

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C12Q 1/68, C07K 14/705, 16/28	A2	(11) International Publication Number: WO 98/50549 (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: PCT/US98/09048 (22) International Filing Date: 7 May 1998 (07.05.98) (30) Priority Data: 08/852,824 7 May 1997 (07.05.97) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). LI, Yi [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). (74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: TWO HUMAN G-PROTEIN COUPLED RECEPTORS: EBV-INDUCED GPCR 2 (EBI-2) AND EDG-I-LIKE GPCR (57) Abstract Two human G-protein coupled receptor polypeptides and DNA (RNA) encoding each of such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the nucleic acid sequence of each of the G-protein coupled receptors.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TWO HUMAN G-PROTEIN COUPLED RECEPTORS: EBV-INDUCED GPCR 2 (EBI-2) AND EDG-1-LIKE GPCR

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are a human EBV-induced G-protein coupled receptor (EBI-2) and a human EDG-1-like G-protein coupled receptor, sometimes hereinafter referred to singularly as "GBR" or "GPCR" and collectively as "GBRs." The invention also relates to inhibiting the action of such polypeptides.

At least nine genes have been identified that are apparently activated in response to an Epstein-Barr Virus (EBV) infection. One of two novel genes also identified in such studies of EBV infections was a novel GPCR-like cDNA molecule designated EBV-induced G-protein coupled receptor (EBI)-1.

Additionally, previously identified was an endothelium-differentiation gene (EDG) that was obtained from PMA-simulated human endothelial cells. Rat and sheep homologs of EDG-1 have been identified, which are also G-protein coupled receptors.

It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers, e.g., cAMP (Lefkowitz, Nature, 351:353-354 (1991)). Herein these proteins are referred to as proteins participating in pathways with G-proteins or PPG proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka, B.K., et al., PNAS, 84:46-50 (1987); Kobilka, B.K., et al., Science, 238:650-656 (1987); Bunzow, J.R., et al., Nature, 336:783-787 (1988)), G-proteins themselves, effector proteins, e.g., phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 252:802-8 (1991)).

For example, in one form of signal transduction, the effect of hormone binding is activation of an enzyme, adenylyl cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP, and GTP also influences hormone binding. A G-protein connects the hormone receptors to adenylyl cyclase. G-protein was shown to exchange GTP for bound GDP when activated by hormone receptors. The GTP-carrying form then binds to an activated adenylyl cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls

the duration of the signal.

The membrane protein gene superfamily of G-protein coupled receptors has been characterized as having seven putative transmembrane domains. The domains are believed to represent transmembrane α -helices connected by extracellular or cytoplasmic loops. A function
5 G-protein is a trimer which consists of a variable alpha subunit coupled to a much more tightly-associated and constant beta and gamma subunits. A broad range of ligands (more than twenty) have been identified which function through GPCRs. In general, bind of an appropriate ligand to a GPCR leads to the activation of the receptor. G-protein coupled receptors include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuroreceptors. Such
10 an activated receptor initiates the regulatory cycle of the G-protein. This cycle consists of GTP exchange for GDP, dissociation of the alpha and beta/gamma subunits, activation of the second messenger pathway by a complex of GTP and the alpha subunit of the G-protein, and return to the resting state by GTP hydrolysis via the innate GTP-ase activity of the G-protein alpha subunit.

G-protein coupled receptors have been characterized as including these seven conserved
15 hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. The G-protein family of coupled receptors includes dopamine receptors which bind to neuroleptic drugs used for treating psychotic and neurological disorders. Other examples of members of this family include calcitonin, adrenergic, endothelin, cAMP, adenosine, muscarinic, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone,
20 opsins and rhodopsins, odorant, cytomegalovirus receptors, etc.

Most GPRs have single conserved cysteine residues in each of the first two extracellular loops which form disulfide bonds that are believed to stabilize functional protein structure. The 7 transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 is also implicated in signal transduction.

25 Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues can influence signal transduction of some GPRs. Most GPRs contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus. For several GPRs, such as the β -adrenoreceptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

30 The ligand binding sites of GPRs are believed to comprise a hydrophilic socket formed by several GPR transmembrane domains, which socket is surrounded by hydrophobic residues of the GPRs. The hydrophilic side of each GPR transmembrane helix is postulated to face inward and form the polar ligand binding site. TM3 has been implicated in several GPRs as having a ligand

binding site, such as including the TM3 aspartate residue. Additionally, TM5 serines, a TM6 asparagine and TM6 or TM7 phenylalanines or tyrosines are also implicated in ligand binding.

GPRs can be intracellularly coupled by heterotrimeric G- proteins to various intracellular enzymes, ion channels and transporters (see, Johnson *et al.*, Endoc., Rev., 10:317-331 (1989)).

5 Different G-protein α -subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of GPRs has been identified as an important mechanism for the regulation of G-protein coupling of some GPRs.

G-protein coupled receptors are found in numerous sites within a mammalian host, for example, dopamine is a critical neurotransmitter in the central nervous system and is a G-protein
10 coupled receptor ligand.

In accordance with one aspect of the present invention, there are provided novel polypeptides, as well as antisense analogs thereof and biologically active and diagnostically or therapeutically useful fragments and derivatives thereof. The polypeptides of the present invention are of human origin.

15 In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules, including mRNAs, DNAs, CDNAS, genomic DNA as well as antisense analogs thereof and biologically active and diagnostically or therapeutically useful fragments thereof.

In accordance with a further aspect of the present invention, there is provided a process for
20 producing such polypeptides by recombinant techniques which comprises culturing recombinant prokaryotic and/or eukaryotic host cells, containing a nucleic acid sequence encoding a polypeptide of the present invention, under conditions promoting expression of said protein and subsequent recovery of said protein.

In accordance with yet a further aspect of the present invention, there are provided
25 antibodies against such polypeptides.

In accordance with another embodiment, there is provided a process for using one or more of the receptors according to the invention to screen for receptor antagonists and/or agonists and/or receptor ligands.

In accordance with still another embodiment of the present invention there is provided a
30 process of using such agonists to activate the polypeptide of the present invention for the treatment of conditions related to the underexpression of the polypeptide of the present invention.

In accordance with another aspect of the present invention there is provided a process of using such antagonists for inhibiting the polypeptide of the present invention for treating

conditions associated with overexpression of the polypeptide of the present invention.

In accordance with yet another aspect of the present invention there is provided non-naturally occurring synthetic, isolated and/or recombinant polypeptides which are fragments, consensus fragments and/or sequences having conservative amino acid substitutions, of at least
5 one transmembrane domain, such that the polypeptides of the present invention may bind ligands, or which may also modulate, quantitatively or qualitatively, ligand binding to the polypeptide of the present invention.

In accordance with still another aspect of the present invention there are provided synthetic or recombinant polypeptides, conservative substitution derivatives thereof, antibodies,
10 anti-idiotypic antibodies, compositions and methods that can be useful as potential modulators of G-protein coupled receptor function, by binding to ligands or modulating ligand binding, due to their expected biological properties, which may be used in diagnostic, therapeutic and/or research applications.

In accordance with another object of the present invention, there is provided synthetic,
15 isolated or recombinant polypeptides which are designed to inhibit or mimic various GPRs or fragments thereof, as receptor types and subtypes.

In accordance with yet another object of the present invention, there is provided a diagnostic assay for detecting a disease or susceptibility to a disease related to a mutation in a nucleic acid sequence encoding a polypeptide of the present invention .

20 These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

Figure 1 shows the cDNA sequence (SEQ ID NO:1) and the corresponding deduced
25 amino acid sequence (SEQ ID NO:2) of the EBV-induced G-protein coupled receptor of the present invention. The polynucleotide sequence contains a 2249 nucleotide sequence which encodes a 342 amino acid ORF. In Figure 1, the standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. Sequencing was performed using a 373 Automated DNA sequencer (Applied Biosystems, Inc.). Sequencing accuracy is predicted to be
30 greater than 97% accurate.

Figure 2 is an amino acid sequence comparison between the EBV-induced (EBI-2) G-Protein Coupled Receptor (upper line, see SEQ ID NO:2) and the human EBI-1 G-Protein Coupled Receptor (lower line, SEQ ID NO:17). The standard one-letter abbreviations are used to

represent the amino acid residues of the amino acid sequences illustrated. The EBI-2 polypeptide according to the invention shows approximately 25% identity and 49% similarity to the amino acid sequence of the EBI-1 gene over an approximately 350 amino acid stretch.

Figure 3 shows the cDNA sequence (SEQ ID NO:3) and the corresponding deduced amino acid sequence (SEQ ID NO:4) of the EDG-1-like G-protein coupled receptor of the present invention. The polynucleotide sequence contains a 1637 nucleotide sequence which encodes a 260 amino acid ORF. In Figure 3, the standard one-letter abbreviation for amino acids is used to illustrate the deduced amino acid sequence. Sequencing was performed using a 373 Automated DNA sequencer (Applied Biosystems, Inc.). Sequencing accuracy is predicted to be greater than 97% accurate.

Figure 4 is an amino acid sequence comparison between the EDG-1-like G-Protein Coupled Receptor (upper line, see SEQ ID NO:4) and the human EDG-1 orphan G-Protein Coupled Receptor (lower line, SEQ ID NO:18). The standard one-letter abbreviations are used to represent the amino acid residues of the amino acid sequences illustrated. The EDG-1-like polypeptide according to the invention shows approximately 54% identity and 73% similarity to the amino acid sequence of the human EDG-1 orphan G-protein Coupled Receptor gene over two regions totaling approximately 120 amino acids.

In accordance with an aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encode for the mature polypeptide having the deduced amino acid sequence of Figure 1 (SEQ ID NO:2) or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 209003 on 4/28/97.

A polynucleotide encoding a EBI-2 polypeptide of the present invention may be found in a cDNA library from umbilical vein endothelial cells, neutrophil leukocyte cells, and corpus colosum cells. The polynucleotide of this invention was discovered in a cDNA library derived from umbilical vein endothelial cells. As described above, it is structurally related to the G protein-coupled receptor family. It contains an open reading frame encoding a protein of 343 amino acid residues.

In accordance with an aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encode for the mature polypeptide having the deduced amino acid sequence of Figure 3 (SEQ ID NO:4) or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 209004 on 4/28/97.

A polynucleotide encoding an EDG-1-like G-protein coupled receptor polypeptide of the present invention may be found in an activated neutrophil cDNA library, cyclohexamine-treated

Raji cells, the RSR;11 bone marrow cell line, activated T-cells, tonsils, and CD34-positive cord blood cells. Northern blot analyses indicate that the EDG-1-like receptor gene is expressed primarily in leukocytes, but expression may also be observed in placenta, spleen, thymus, lung and pancreas tissue. The polynucleotide of this invention was discovered in a cDNA library
5 derived from activated neutrophils. As described above, it is structurally related to the G protein-coupled receptor family. It contains an open reading frame encoding a protein of 261 amino acid residues.

As noted above a great deal of the importance attributed to GPCR molecules such as those of the presently claimed invention lies in the diversity of biological functions in which they
10 participate. For example, it is thought that, upon release from the alpha subunit, the beta/gamma subunit may also play a functional role in the regulation of signal transduction by activating the arachidonic acid signal transduction pathway via the activation of phospholipase A_2 . In addition, GPCR molecules and their associated G-proteins have been implicated in the coupling of visual pigments to cGMP phosphodiesterase, phosphatidyl inositol (PI) turnover, adenylyl cyclase signal
15 channels and other integral membrane enzymes to transporter proteins. As a result, it is apparent that novel GPCR molecules may prove useful in a wide variety of pharmaceutical applications including research and development. For example, target based screens for small molecules and other such pharmacologically valuable factors may be based on activating a given GPCR. It has also been observed that short peptides may function by mimicking the GPCR (termed
20 receptomimetics). Furthermore, monoclonal antibodies raised against such factors may prove useful as therapeutics in a number of capacities. Potential therapeutic and/or diagnostic applications for such a factor may include such diverse clinical presentations as heart disease, mental illness, cancer, atherosclerosis, restenosis, Alzheimer's Disease, Parkinson's Disease, and a number of others.

Accordingly, the polynucleotides of the present invention may be in the form of RNA or
25 in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature EBI-2 polypeptide may be identical to the coding sequence shown in Figure 1 (SEQ ID NO:1) or that of
30 the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of Figure 1 (SEQ ID NO:1) or the deposited cDNA. Similarly, the coding sequence which encodes the mature EDG-1-like G-protein coupled receptor polypeptide may be identical to the

coding sequence shown in Figure 3 (SEQ ID NO:3) or that of the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of Figure 3 (SEQ ID NO:3) or the deposited cDNA.

5 The polynucleotides which encode either (a) the mature EBI-2 polypeptide of Figure 1 (SEQ ID NO:2) or the mature EBI-2 polypeptide encoded by the deposited cDNA, or (b) the mature EDG-1-like G-protein coupled receptor polypeptide of Figure 3 (SEQ ID NO:4) or the mature EDG-1-like G-protein coupled receptor polypeptide encoded by the deposited cDNA may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature
10 polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding sequence 5' and/or 3' of the coding sequence for the mature polypeptide.

Thus, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide
15 which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of (a) the polypeptide having the deduced amino acid sequence of Figure 1 (SEQ ID NO:2) or the polypeptide encoded
20 by the cDNA of the deposited clone, or (2) the polypeptide having the deduced amino acid sequence of Figure 3 (SEQ ID NO:4) or the polypeptide encoded by the cDNA of the deposited clone. The variant of either of these two polynucleotides may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.

Thus, the present invention includes polynucleotides encoding the same mature
25 polypeptide as shown in Figure 1 (SEQ ID NO:2) or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of Figure 1 (SEQ ID NO:2) or the polypeptide encoded by the cDNA of the deposited clone. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

30 Likewise, the present invention includes polynucleotides encoding the same mature polypeptide as shown in Figure 3 (SEQ ID NO:4) or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of Figure 3 (SEQ ID NO:4) or the

polypeptide encoded by the cDNA of the deposited clone. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

As hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in Figure 1 (SEQ ID NO:1) or of the coding sequence of the deposited clone. Also, as hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in Figure 3 (SEQ ID NO:3) or of the coding sequence of the deposited clone. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

The present invention also includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide sequence which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell.

The polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature form of the polypeptide. The polynucleotides may also code for a proprotein which is the mature protein plus additional 5' amino acid residues. A mature protein having a prosequence is a proprotein and is an inactive form of the protein. Once the prosequence is cleaved an active mature protein remains. Thus, for example, the polynucleotide of the present invention may encode a mature protein, or a protein having a prosequence or for a protein having both a prosequence and a presequence (leader sequence).

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention. The marker sequence may be a hexa-histidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

Fragments of the full length gene of the present invention may be used as hybridization probes for a cDNA or a genomic library to isolate the full length DNA and to isolate other DNAs

which have a high sequence similarity to the gene or similar biological activity. Probes of this type preferably have at least 10, preferably at least 15, and even more preferably at least 30 bases and may contain, for example, at least 50 or more bases. In fact, probes of this type having at least up to 150 bases or greater may be preferably utilized. The probe may also be used to
5 identify a DNA clone corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promotor regions, exons and introns. An example of a screen comprises isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary or identical to that of the gene or portion of the gene sequences of the present
10 invention are used to screen a library of genomic DNA to determine which members of the library the probe hybridizes to.

It is also appreciated that such probes can be and are preferably labeled with an analytically detectable reagent to facilitate identification of the probe. Useful reagents include but are not limited to radioactivity, fluorescent dyes or enzymes capable of catalyzing the formation
15 of a detectable product. The probes are thus useful to isolate complementary copies of DNA from other sources or to screen such sources for related sequences.

The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between the sequences. (As indicated above, 70% identity would
20 include within such definition a 70 bps fragment taken from a 100 bp polynucleotide. for example.) The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the
25 hereinabove described polynucleotides in a preferred embodiment encode enzymes which either retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Figures 1 and 3 (SEQ ID NOS:2 and 4, respectively. In referring to identity in the case of hybridization, as known in the art, such identity refers to complementarity of polynucleotide segments.

30 Alternatively, the polynucleotide may have at least 15 bases, preferably at least 30 bases, and more preferably at least 50 bases which hybridize to any part of a polynucleotide of the present invention and which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides may be employed as probes for the

polynucleotides of SEQ ID NOS:1 and 3, for example, for recovery of the polynucleotide or as a diagnostic probe or as a PCR primer.

Thus, the present invention is directed to polynucleotides having at least a 70% identity, preferably at least 90% identity and more preferably at least a 95% identity to a polynucleotide which encodes either the polypeptide of SEQ ID NO:2, or the polypeptide of SEQ ID NO:4, as well as fragments thereof, which fragments have at least 15 bases, preferably at least 30 bases, more preferably at least 50 bases and most preferably fragments having up to at least 150 bases or greater, which fragments are at least 90% identical, preferably at least 95% identical and most preferably at least 97% identical to any portion of a polynucleotide of the present invention.

The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. 112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

The present invention further relates to polypeptides which have the deduced amino acid sequences of Figures 1 and 3 (SEQ ID NOS:2 and 4, respectively) as well as fragments, analogs and derivatives of such polypeptides.

The terms "fragment," "derivative" and "analog" when referring to (a) the polypeptide of Figure 1 (SEQ ID NO:2) or that encoded by the deposited cDNA, or (b) the polypeptide of Figure 3 (SEQ ID NO:4), means a polypeptide which either retains substantially the same biological function or activity as such polypeptide, i.e. functions as a G-protein coupled receptor, or retains the ability to bind the ligand or the receptor even though the polypeptide does not function as a G-protein coupled receptor, for example, a soluble form of the receptor.

The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

The fragment, derivative or analog of either (a) the polypeptide of Figure 1 (SEQ ID NO:2) or that encoded by the deposited cDNA, (b) the polypeptide of Figure 3 (SEQ ID NO:4) may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in

which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, or (v) one in which a fragment of the polypeptide is soluble, i.e. not membrane bound, yet still binds ligands to the membrane bound receptor. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The polypeptides of the present invention include the polypeptides of SEQ ID NOS:2 and 4 (in particular the respective mature polypeptides) as well as polypeptides which have at least 70% similarity (preferably at least a 70% identity) to either the polypeptide of SEQ ID NO:2 or the polypeptide of SEQ ID NO:4 and more preferably at least a 90% similarity (more preferably at least a 90% identity) to the polypeptide of SEQ ID NO:2 or of SEQ ID NO:4 and still more preferably at least a 95% similarity (still more preferably a 90% identity) to the polypeptide of SEQ ID NO:2 or of SEQ ID NO:4 and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

As known in the art "similarity" between two polypeptides is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide.

Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

The present invention also relates to a method for identifying and/or isolating cells, tissues, or classes of cells or tissues, by utilizing probes of the polynucleotides that encode the EBI-2 G-protein coupled receptor polypeptide or by utilizing an antibody specific for the EBI-2 G-protein coupled receptor, for example. Since the EBI-2 G-protein coupled receptor polypeptides according to the invention occur in vein endothelial cells, neutrophil leukocyte cells and corpus colosum cells, the above probes or antibodies, for example, may be utilized to identify and/or isolate such cells, tissues or classes of cells or tissues.

The present invention further relates to a method for identifying and/or isolating cells, tissues, or classes of cells or tissues, by utilizing probes of the polynucleotides that encode the EDG-1-like G-protein coupled receptor polypeptide or by utilizing an antibody specific for the EDG-1-like G-protein coupled receptor polypeptide, for example. Since the EDG-1-like G-protein coupled receptor polypeptides according to the invention occur in leukocyte, tonsil, placenta, thymus, lung and pancreas tissue, the above probes or antibodies, for example, may be utilized to identify and/or isolate such cells, tissues or classes of cells or tissues.

The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.

The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the G-protein coupled receptor genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by

procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli, lac or trp, the phage lambda P_L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are PKK232-8 and PCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation. (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition. Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is

assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell*, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and

also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

5 The G-protein coupled receptor polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in
10 completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

 The polypeptides of the present invention may be a naturally purified product, or a **product** of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in
15 culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

 The G-protein coupled receptor of the present invention may be employed in a process for screening for antagonists and/or agonists for the receptor.

20 In general, such screening procedures involve providing appropriate cells which express the receptor on the surface thereof. In particular, a polynucleotide encoding the receptor of the present invention is employed to transfect cells to thereby express the G-protein coupled receptor. Such transfection may be accomplished by procedures as hereinabove described.

 One such screening procedure involves the use of the melanophores which are transfected
25 to express the G-protein coupled receptor of the present invention. Such a screening technique is described in PCT WO 92/01810 published February 6, 1992.

 Thus, for example, such assay may be employed for screening for a receptor antagonist by contacting the melanophore cells which encode the G-protein coupled receptor with both the receptor ligand and a compound to be screened. Inhibition of the signal generated by the ligand
30 indicates that a compound is a potential antagonist for the receptor, i.e., inhibits activation of the receptor.

 The screen may be employed for determining an agonist by contacting such cells with compounds to be screened and determining whether such compound generates a signal, i.e.,

activates the receptor.

Other screening techniques include the use of cells which express the G-protein coupled receptor (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation, for example, as described in Science, volume 246, pages 181-296 (October 1989). For example, potential agonists or antagonists may be contacted with a cell which expresses the G-protein coupled receptor and a second messenger response, e.g. signal transduction or pH changes, may be measured to determine whether the potential agonist or antagonist is effective.

Another such screening technique involves introducing RNA encoding the G-protein coupled receptor into xenopus oocytes to transiently express the receptor. The receptor oocytes may then be contacted in the case of antagonist screening with the receptor ligand and a compound to be screened, followed by detection of inhibition of a calcium signal.

Another screening technique involves expressing the G-protein coupled receptor in which the receptor is linked to a phospholipase C or D. As representative examples of such cells, there may be mentioned endothelial cells, smooth muscle cells, embryonic kidney cells, etc. The screening for an antagonist or agonist may be accomplished as hereinabove described by detecting activation of the receptor or inhibition of activation of the receptor from the phospholipase second signal.

Another method involves screening for antagonists by determining inhibition of binding of labeled ligand to cells which have the receptor on the surface thereof. Such a method involves transfecting a eukaryotic cell with DNA encoding the G-protein coupled receptor such that the cell expresses the receptor on its surface and contacting the cell with a potential antagonist in the presence of a labeled form of a known ligand. The ligand can be labeled, e.g., by radioactivity. The amount of labeled ligand bound to the receptors is measured, e.g., by measuring radioactivity of the receptors. If the potential antagonist binds to the receptor as determined by a reduction of labeled ligand which binds to the receptors, the binding of labeled ligand to the receptor is inhibited.

The present invention also provides a method for determining whether a ligand not known to be capable of binding to a G-protein coupled receptor can bind to such receptor which comprises contacting a mammalian cell which expresses a G-protein coupled receptor with the ligand under conditions permitting binding of ligands to the G-protein coupled receptor, detecting the presence of a ligand which binds to the receptor and thereby determining whether the ligand binds to the G-protein coupled receptor. The systems hereinabove described for determining

agonists and/or antagonists may also be employed for determining ligands which bind to the receptor.

In general, antagonists for G-protein coupled receptors which are determined by screening procedures may be employed for a variety of therapeutic purposes. For example, such antagonists have been employed for treatment of hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, psychoses, depression, migraine, vomiting, stroke, eating disorders, migraine headaches, cancer and benign prostatic hypertrophy.

Agonists for G-protein coupled receptors are also useful for therapeutic purposes, such as the treatment of asthma, Parkinson's disease, acute heart failure, hypotension, urinary retention, and osteoporosis.

Examples of G-protein coupled receptor antagonists include an antibody, or in some cases an oligonucleotide, which binds to the G-protein coupled receptor but does not elicit a second messenger response such that the activity of the G-protein coupled receptor is prevented. Antibodies include anti-idiotypic antibodies which recognize unique determinants generally associated with the antigen-binding site of an antibody. Potential antagonists also include proteins which are closely related to the ligand of the G-protein coupled receptor, i.e. a fragment of the ligand, which have lost biological function and when binding to the G-protein coupled receptor, elicit no response.

A potential antagonist also includes an antisense construct prepared through the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the mature polypeptides of the present invention, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix -see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al. Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991)), thereby preventing transcription and the production of G-protein coupled receptor. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the G-protein coupled receptor (antisense - Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of G-protein coupled receptor.

Another potential antagonist is a small molecule which binds to the G-protein coupled receptor, making it inaccessible to ligands such that normal biological activity is prevented. Examples of small molecules include but are not limited to small peptides or peptide-like molecules.

5 Potential antagonists also include a soluble form of a G-protein coupled receptor, e.g. a fragment of the receptor, which binds to the ligand and prevents the ligand from interacting with membrane bound G-protein coupled receptors.

The G-protein coupled receptor and antagonists or agonists may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a
10 therapeutically effective amount of the polypeptide, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

The invention also provides a pharmaceutical pack or kit comprising one or more
15 containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the pharmaceutical compositions may be employed in conjunction
20 with other therapeutic compounds.

The pharmaceutical compositions may be administered in a convenient manner such as by the topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes. The pharmaceutical compositions are administered in an amount which is effective for treating and/or prophylaxis of the specific indication. In general, the pharmaceutical compositions
25 will be administered in an amount of at least about 10 g/kg body weight and in most cases they will be administered in an amount not in excess of about 8 mg/Kg body weight per day. In most cases, the dosage is from about 10 g/kg to about 1 mg/kg body weight daily, taking into account the routes of administration, symptoms, etc.

The G-protein coupled receptor polypeptides and antagonists or agonists which are
30 polypeptides, may be employed in accordance with the present invention by expression of such polypeptides *in vivo*, which is often referred to as "gene therapy."

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) encoding a polypeptide *ex vivo*, with the engineered cells then being provided to a patient

to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by, for example, procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for administering a polypeptide of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells *in vivo* after combination with a suitable delivery vehicle.

Retroviruses from which the retroviral plasmid vectors hereinabove mentioned may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus. In one embodiment, the retroviral plasmid vector is derived from Moloney Murine Leukemia Virus.

The vector includes one or more promoters. Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller, et al., Biotechniques, Vol. 7, No. 9, 980-990 (1989), or any other promoter (e.g., cellular promoters such as eukaryotic cellular promoters including, but not limited to, the histone, pol III, and β -actin promoters). Other viral promoters which may be employed include, but are not limited to, adenovirus promoters, thymidine kinase (TK) promoters, and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.

The nucleic acid sequence encoding the polypeptide of the present invention is under the control of a suitable promoter. Suitable promoters which may be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral

LTRs (including the modified retroviral LTRs hereinabove described); the β -actin promoter; and human growth hormone promoters. The promoter also may be the native promoter which controls the gene encoding the polypeptide.

5 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, ψ -2, ψ -AM, PA12, T19-14X, VT-19-17-H2, ψ CRE, ψ CRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy, Vol. 1, pgs. 5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are
10 not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be
15 employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

20 G-protein coupled receptors are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds which stimulate a G-protein coupled receptor and compounds which antagonize a G-protein coupled receptor.

This invention further provides a method of identifying compounds which specifically
25 interact with, and bind to, the human G-protein coupled receptors on the surface of a cell which comprises contacting a mammalian cell comprising an isolated DNA molecule encoding the G-protein coupled receptor with a plurality of compounds, determining those which bind to the mammalian cell, and thereby identifying compounds which specifically interact with and bind to a human G-protein coupled receptor of the present invention.

30 This invention also provides a method of detecting expression of the G-protein coupled receptor on the surface of a cell by detecting the presence of mRNA coding for a G-protein coupled receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with a nucleic acid probe comprising a nucleic acid molecule of at least 15

nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding a human G-protein coupled receptor under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the G-protein coupled receptor by the cell.

5 This invention is also related to the use of the G-protein coupled receptor gene as part of a diagnostic assay for detecting diseases or susceptibility to diseases related to the presence of mutated G-protein coupled receptor genes. Such diseases are related to cell transformation, such as tumors and cancers.

10 Individuals carrying mutations in the human G-protein coupled receptor gene may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a patient's cells, such as from blood, urine, saliva, tissue biopsy and autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki *et al.*, Nature, 324:163-166 (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid
15 encoding the G-protein coupled receptor protein can be used to identify and analyze G-protein coupled receptor mutations. For example, deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to radiolabeled G-protein coupled receptor RNA or alternatively, radiolabeled G-protein coupled receptor antisense DNA sequences. Perfectly
20 matched sequences can be distinguished from mismatched duplexes by RNase A digestion or by differences in melting temperatures.

Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis.
25 DNA fragments of different sequences may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers *et al.*, Science, 230:1242 (1985)).

30 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (e.g., Cotton *et al.*, PNAS, USA, 85:4397-4401 (1985)).

Thus, the detection of a specific DNA sequence may be achieved by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of

restriction enzymes, (e.g., Restriction Fragment Length Polymorphisms (RFLP)) and Southern blotting of genomic DNA.

In addition to more conventional gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

5 The present invention also relates to a diagnostic assay for detecting altered levels of soluble forms of the receptor polypeptides of the present invention in various tissues. Assays used to detect levels of the soluble receptor polypeptides in a sample derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive-binding assays, Western blot analysis and preferably as ELISA assay.

10 An ELISA assay initially comprises preparing an antibody specific to antigens of the G-protein coupled receptor polypeptides, preferably a monoclonal antibody. In addition a reporter antibody is prepared against the monoclonal antibody. To the reporter antibody is attached a detectable reagent such as radioactivity, fluorescence or in this example a horseradish peroxidase enzyme. A sample is now removed from a host and incubated on a solid support, e.g. a
15 polystyrene dish, that binds the proteins in the sample. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the monoclonal antibody is incubated in the dish during which time the monoclonal antibodies attach to any G-protein coupled receptor proteins attached to the polystyrene dish. All unbound monoclonal antibody is washed out with buffer. The reporter antibody linked to horseradish
20 peroxidase is now placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to G-protein receptor proteins. Unattached reporter antibody is then washed out. Peroxidase substrates are then added to the dish and the amount of color developed in a given time period is a measurement of the amount of G-protein coupled receptor proteins present in a given volume of patient sample when compared against a standard curve.

25 The sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of
30 DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3' untranslated region is used to rapidly

select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

5 PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-
10 sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma et al.,
15 Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases
20 that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the
25 causative agent of the disease.

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).

30 The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an

Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention. Also, transgenic mice may be used to express humanized antibodies to immunogenic polypeptide products of this invention.

The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All parts or amounts, unless otherwise specified, are by weight.

In order to facilitate understanding of the following examples certain frequently occurring methods and/or terms will be described.

"Plasmids" are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

"Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 µg of

plasmid or DNA fragment is used with about 2 units of enzyme in about 20 µl of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.

Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. *et al.*, Nucleic Acids Res., 8:4057 (1980).

"Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase ("ligase") per 0.5 µg of approximately equimolar amounts of the DNA fragments to be ligated.

Unless otherwise stated, transformation was performed as described in the method of Graham, F. and Van der Eb, A., Virology, 52:456-457 (1973).

Example 1

Bacterial Expression and Purification of EBI-2

The DNA sequence encoding EBI-2, ATCC # 209003, is initially amplified using PCR oligonucleotide primers corresponding to the 5' sequences of the processed EBI-2 protein (minus the signal peptide sequence) and the vector sequences 3' to the EBI-2 gene. Additional nucleotides corresponding to EBI-2 were added to the 5' and 3' sequences respectively. The 5' oligonucleotide primer has the sequence 5' CCGAGGATCCATGCAAGCCGTCGACAAT 3' (SEQ ID NO:5) contains a BamHI restriction enzyme site followed by 18 nucleotides of the EBI-2 coding sequence starting from the presumed terminal amino acid of the processed protein codon. The 3' sequence 5' CCGAGGATCCTTACATTGGAGTCTCTTC 3' (SEQ ID NO:6)

contains complementary sequences to BamHI site and is followed by 18 nucleotides of EBI-2. The restriction enzyme sites correspond to the restriction enzyme sites on the bacterial expression vector pQE-60. (Qiagen, Inc., Chatsworth, CA, 91311). pQE-60 encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites. pQE-60 was then digested with BamHI. The amplified sequences were ligated into pQE-60 and were inserted in frame with the sequence encoding for the histidine tag and the RBS. The ligation mixture was then used to transform *E. coli* strain M15/rep 4 (Qiagen, Inc.) by the procedure described in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989). M15/rep4 contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells were grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside") was then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation. The cell pellet was solubilized in the chaotropic agent 6 Molar Guanidine HCl. After clarification, solubilized hSca-2 was purified from this solution by chromatography on a Nickel-Chelate column under conditions that allow for tight binding by proteins containing the 6-His tag (Hochuli, E. et al., J. Chromatography 411:177-184 (1984)). hSca-2 (95 % pure was eluted from the column in 6 molar guanidine HCl pH 5.0 and for the purpose of renaturation adjusted to 3 molar guanidine HCl, 100mM sodium phosphate, 10 mmolar glutathione (reduced) and 2 mmolar glutathione (oxidized). After incubation in this solution for 12 hours the protein was dialyzed to 10 mmolar sodium phosphate.

Example 2

Cloning and expression of EBI-2 using the baculovirus expression system

The DNA sequence encoding the full length EBI-2 protein, ATCC # 209003, was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the

gene:

The 5' primer has the sequence 5' CCGAGGATCCGCCATCA-TGCAAGCCGTCGACAAT 3' (SEQ ID NO:7) and contains a BamHI restriction enzyme site (in bold) followed by 6 nucleotides resembling an efficient signal for the initiation of translation in eukaryotic cells (Kozak, M., J. Mol. Biol., 196:947-950 (1987) which is just behind the first 18 nucleotides of the EBI-2 gene (the initiation codon for translation "ATG" is underlined).

The 3' primer has the sequence 5' CCGAGGATCCT-TACATTGGAGTCTCTTC 3' (SEQ ID NO:8) and contains the cleavage site for the restriction endonuclease BamHI and 18 nucleotides complementary to the 3' translated sequence of the extracellular part of EBI-2. The amplified sequences were isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment was then digested with the endonucleases BamHI. and purified again on a 1% agarose gel. This fragment is designated F2.

The vector pA2 (modification of pVL941 vector, discussed below) is used for the expression of the EBI-2 protein using the baculovirus expression system (for review see: Summers, M.D. and Smith, G.E. 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experimental Station Bulletin No. 1555). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the recognition sites for the restriction endonucleases BamHI. The polyadenylation site of the simian virus (SV)40 is used for efficient polyadenylation. For an easy selection of recombinant virus the beta-galactosidase gene from E.coli is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin sequences are flanked at both sides by viral sequences for the cell-mediated homologous recombination of co-transfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pA2 such as pRG1 and pA2-GP in which case the 5' primer are changed accordingly, and pAc373, pVL941 and pAcIM1 (Luckow, V.A. and Summers, M.D., Virology, 170:31-39).

The plasmid was digested with the restriction enzyme BamHI and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The DNA was then isolated from a 1% agarose gel using the commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.). This vector DNA is designated V2.

Fragment F2 and the dephosphorylated plasmid V2 were ligated with T4 DNA ligase. E.coli HB101 cells were then transformed and bacteria identified that contained the plasmid (pBacEBI-2) with the EBI-2 gene using the enzyme BamHI. The sequence of the cloned

fragment was confirmed by DNA sequencing.

5 μ g of the plasmid pBacEBI-2 was co-transfected with 1.0 μ g of a commercially available linearized baculovirus ("BaculoGold baculovirus DNA", Pharmingen, San Diego, CA.) using the lipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)).

5 1 μ g of BaculoGold virus DNA and 5 μ g of the plasmid pBacEBI-2 were mixed in a sterile well of a microtiter plate containing 50 μ l of serum free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards 10 μ l Lipofectin plus 90 μ l Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added drop-wise to the Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue
10 culture plate with 1 ml Grace's medium without serum. The plate was rocked back and forth to mix the newly added solution. The plate was then incubated for 5 hours at 27 C. After 5 hours the
transfection solution was removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum was added. The plate was put back into an incubator and
15 cultivation continued at 27 C for four days.

After four days the supernatant was collected and a plaque assay performed similar as described by Summers and Smith (supra). As a modification an agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) was used which allows an easy isolation of blue stained plaques. (A detailed description of a "plaque assay" can also be found in the user's guide for insect cell
20 culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10).

Four days after the serial dilution, the virus was added to the cells and blue stained plaques were picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruses was then resuspended in an Eppendorf tube containing 200 μ l of Grace's medium. The agar was removed by a brief centrifugation and the supernatant containing the recombinant baculovirus was
25 used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes were harvested and then stored at 4 C.

Sf9 cells were grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells were infected with the recombinant baculovirus V-EBI-2 at a multiplicity of infection (MOI) of 2. Six hours later the medium was removed and replaced with SF900 II medium minus
30 methionine and cysteine (Life Technologies Inc., Gaithersburg). 42 hours later 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S cysteine (Amersham) were added. The cells were further incubated for 16 hours before they were harvested by centrifugation and the labelled proteins visualized by SDS-PAGE and autoradiography.

Example 3

Expression of Recombinant EBI-2 in COS cells

5 The expression of plasmid, EBI-2 HA is derived from a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin resistance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, an SV40 intron and polyadenylation site. A DNA fragment encoding the entire EBI-2 precursor and a HA tag fused in frame to its 3' end was cloned into the polylinker region of the vector, therefore, the recombinant protein
10 expression is directed under the CMV promoter. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein as previously described (I. Wilson, H. Niman, R. Heighen, A. Cherenson, M. Connolly, and R. Lerner, 1984, Cell 37:767, (1984)). The infusion of HA tag to the target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.

15 The plasmid construction strategy is described as follows:

The DNA sequence encoding EBI-2, ATCC # 209003, was constructed by PCR using two primers: the 5' primer 5' CCGAGGATCCGCCATCATGCAAGCCGTCGACAAT 3' (SEQ ID NO:9) contains a BamHI site followed by EBI-2 coding sequence starting from the initiation
20 codon; the 3' sequence 5' CCGATCTAGATTAATCCCATACGACGTCCCAGACTACGCTCATTGGAGTCTCTTC 3' (SEQ ID NO:10) contains complementary sequences to XbaI site, translation stop codon, HA tag and EBI-2 coding sequence (not including the stop codon). Therefore, the PCR product contains a BamHI site, EBI-2 coding sequence followed by HA tag fused in frame, a translation termination stop codon next to the HA tag, and an XbaI site. The PCR amplified DNA fragment
25 and the vector, pcDNAI/Amp, were digested with BamHI and XbaI restriction enzyme and ligated. The ligation mixture was transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037) the transformed culture was plated on ampicillin media plates and resistant colonies were selected. Plasmid DNA was isolated from transformants and examined by restriction analysis for the presence of the correct
30 fragment. For expression of the recombinant EBI-2 COS cells were transfected with the expression vector by DEAE-DEXTRAN method (J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expression of the EBI-2 HA protein was detected by radiolabelling and immunoprecipitation method (E. Harlow.

D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cells were labelled for 8 hours with ^{35}S -cysteine two days post transfection. Culture media was then collected and cells were lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50mM Tris, pH 7.5) (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysate and culture media were precipitated with an HA specific monoclonal antibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels.

Example 4

Expression via Gene Therapy

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin, is added. This is then incubated at 37 C for approximately one week. At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al, DNA, 7:219-25 (1988) flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention is amplified using PCR primers which correspond to the 5' and 3' end sequences respectively. The 5' primer containing an EcoRI site and the 3' primer further includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is used to transform bacteria HB101, which are then plated onto agar-containing kanamycin for the purpose of confirming that the vector had the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and

the packaging cells are transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product.

Example 5

Bacterial Expression and Purification of EDG-1-Like Polypeptide

The DNA sequence encoding EDG-1-like polypeptide, ATCC # 209004, is initially amplified using PCR oligonucleotide primers corresponding to the 5' sequences of the processed EDG-1-like polypeptide protein (minus the signal peptide sequence) and the vector sequences 3' to the EDG-1-like polypeptide gene. Additional nucleotides corresponding to EBI-2 were added to the 5' and 3' sequences respectively. The 5' oligonucleotide primer has the sequence 5' CCGAGGATC-CATGAACGCCACGGGGACC 3' (SEQ ID NO:11) contains a BamHI restriction enzyme site followed by 18 nucleotides of the EDG-1-like polypeptide coding sequence starting from the presumed terminal amino acid of the processed protein codon. The 3' sequence 5' CCGAGGATCCTCAGATGCTCCGCACGCT 3' (SEQ ID NO:12) contains complementary sequences to BamHI site and is followed by 18 nucleotides of EDG-1-like polypeptide. The restriction enzyme sites correspond to the restriction enzyme sites on the bacterial expression vector pQE-60. (Qiagen, Inc., Chatsworth, CA, 91311). pQE-60 encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites. pQE-60 was then digested with BamHI. The amplified sequences were ligated into pQE-60 and were inserted in frame with the sequence encoding for the histidine tag and the RBS. The ligation mixture was then used to transform E. coli strain M15/rep 4 (Qiagen, Inc.) by the procedure described in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual. Cold Spring

Laboratory Press, (1989). M15/rep4 contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the
5 desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells were grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside") was then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased
10 gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation. The cell pellet was solubilized in the chaotropic agent 6 Molar Guanidine HCl. After clarification, solubilized EBI-2 was purified from this solution by chromatography on a Nickel-Chelate column under conditions that allow for tight binding by proteins containing the 6-His tag (Hochuli, E. et al., J. Chromatography 411:177-184.(1984)). EBI-2 (95 % pure was eluted
15 from the column in 6 molar guanidine HCl pH 5.0 and for the purpose of renaturation adjusted to 3 molar guanidine HCl, 100mM sodium phosphate, 10 mmolar glutathione (reduced) and 2 mmolar glutathione (oxidized). After incubation in this solution for 12 hours the protein was dialyzed to 10 mmolar sodium phosphate.

Example 6

Cloning and expression of EDG-1-like polypeptide using the baculovirus expression system

The DNA sequence encoding the full length EDG-1-like polypeptide protein. ATCC # 209004, was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene:

The 5' primer has the sequence 5' GCGAGGATCCGCCAT-
25 CATGAACGCCACGGGGACC 3' (SEQ ID NO:13) and contains a BamHI restriction enzyme site (in bold) followed by 6 nucleotides resembling an efficient signal for the initiation of translation in eukaryotic cells (Kozak, M., J. Mol. Biol., 196:947-950 (1987) which is just behind the first 18 nucleotides of the EDG-1-like polypeptide gene (the initiation codon for translation "ATG" is underlined).

30 The 3' primer has the sequence 5' CCGAGGATCCTC-AGATGCTCCGCACGCT 3' (SEQ ID NO:14) and contains the cleavage site for the restriction endonuclease BamHI and 18 nucleotides complementary to the 3' translated sequence of the extracellular part of EDG-1-like polypeptide. The amplified sequences were isolated from a 1% agarose gel using a commercially

available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment was then digested with the endonucleases BamHI, and purified again on a 1% agarose gel. This fragment is designated F2.

The vector pA2 (modification of pVL941 vector, discussed below) is used for the expression of the EDG-1-like polypeptide protein using the baculovirus expression system (for review see: Summers, M.D. and Smith, G.E. 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experimental Station Bulletin No. 1555). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the recognition sites for the restriction endonucleases BamHI. The polyadenylation site of the simian virus (SV)40 is used for efficient polyadenylation. For an easy selection of recombinant virus the beta-galactosidase gene from E.coli is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin sequences are flanked at both sides by viral sequences for the cell-mediated homologous recombination of co-transfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pA2 such as pRG1 and pA2-GP in which case the 5' primer are changed accordingly, and pAc373, pVL941 and pAcIM1 (Luckow, V.A. and Summers, M.D., Virology, 170:31-39).

The plasmid was digested with the restriction enzyme BamHI and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The DNA was then isolated from a 1% agarose gel using the commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.). This vector DNA is designated V2.

Fragment F2 and the dephosphorylated plasmid V2 were ligated with T4 DNA ligase. E.coli HB101 cells were then transformed and bacteria identified that contained the plasmid (pBacEDG-1-like polypeptide) with the EDG-1-like polypeptide gene using the enzyme BamHI. The sequence of the cloned fragment was confirmed by DNA sequencing.

5 µg of the plasmid pBacEDG-1-like polypeptide was co-transfected with 1.0 µg of a commercially available linearized baculovirus ("BaculoGold baculovirus DNA", Pharmingen, San Diego, CA.) using the lipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA. 84:7413-7417 (1987)).

1 µg of BaculoGold virus DNA and 5 µg of the plasmid pBacEDG-1-like polypeptide were mixed in a sterile well of a microtiter plate containing 50 µl of serum free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards 10 µl Lipofectin plus 90 µl Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added drop-wise to the Sf9 insect cells (ATCC CRL 1711) seeded in a

35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate was rocked back and forth to mix the newly added solution. The plate was then incubated for 5 hours at 27 C. After 5 hours the transfection solution was removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum was added. The plate was put back into an incubator and cultivation continued at 27 C for four days.

After four days the supernatant was collected and a plaque assay performed similar as described by Summers and Smith (supra). As a modification an agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) was used which allows an easy isolation of blue stained plaques. (A detailed description of a "plaque assay" can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10).

Four days after the serial dilution, the virus was added to the cells and blue stained plaques were picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruses was then resuspended in an Eppendorf tube containing 200 µl of Grace's medium. The agar was removed by a brief centrifugation and the supernatant containing the recombinant baculovirus was used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes were harvested and then stored at 4 C.

Sf9 cells were grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells were infected with the recombinant baculovirus V-EDG-1-like polypeptide at a multiplicity of infection (MOI) of 2. Six hours later the medium was removed and replaced with SF900 II medium minus methionine and cysteine (Life Technologies Inc., Gaithersburg). 42 hours later 5 µCi of ³⁵S-methionine and 5 µCi ³⁵S cysteine (Amersham) were added. The cells were further incubated for 16 hours before they were harvested by centrifugation and the labelled proteins visualized by SDS-PAGE and autoradiography.

Example 7

Expression of Recombinant EDG-1-like Polypeptide in COS cells

The expression of plasmid, EDG-1-like polypeptide HA is derived from a vector pcDNA1/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin resistance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, an SV40 intron and polyadenylation site. A DNA fragment encoding the entire EDG-1-like polypeptide precursor and a HA tag fused in frame to its 3' end was cloned into the polylinker region of the vector, therefore, the recombinant protein expression is directed under the CMV promoter. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein as previously

described (I. Wilson, H. Niman, R. Heighten, A. Cherenson, M. Connolly, and R. Lerner, 1984, Cell 37:767, (1984)). The infusion of HA tag to the target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.

The plasmid construction strategy is described as follows:

5 The DNA sequence encoding EDG-1-like polypeptide, ATCC # 209004, was constructed by PCR using two primers: the 5' primer 5' CCGAGGATCCGCCATCATGAACGCCACGGGGACC 3' (SEQ ID NO:15) contains a BamHI site followed by EDG-1-like polypeptide coding sequence starting from the initiation codon; the 3' sequence 5' CCGATCTAGATCAATCCCATACGACGTCCCAG-
10 ACTACGCTGATGCTCCGCACGCT 3' (SEQ ID NO:16) contains complementary sequences to XbaI site, translation stop codon, HA tag and EDG-1-like polypeptide coding sequence (not including the stop codon). Therefore, the PCR product contains a BamHI site, EDG-1-like polypeptide coding sequence followed by HA tag fused in frame, a translation termination stop codon next to the HA tag, and an XbaI site. The PCR amplified DNA fragment and the vector,
15 pcDNAI/Amp, were digested with BamHI and XbaI restriction enzyme and ligated. The ligation mixture was transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037) the transformed culture was plated on ampicillin media plates and resistant colonies were selected. Plasmid DNA was isolated from transformants and examined by restriction analysis for the presence of the correct fragment. For
20 expression of the recombinant EDG-1-like polypeptide COS cells were transfected with the expression vector by DEAE-DEXTRAN method (J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expression of the EDG-1-like polypeptide HA protein was detected by radiolabelling and immunoprecipitation method (E. Harlow, D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory
25 Press, (1988)). Cells were labelled for 8 hours with ³⁵S-cysteine two days post transfection. Culture media was then collected and cells were lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50mM Tris, pH 7.5) (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysate and culture media were precipitated with an HA specific monoclonal antibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels.

30

Example 8

Expression via Gene Therapy

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in

tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin, is added. This is then incubated at 37 C for approximately one week. At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al, DNA, 7:219-25 (1988) flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention is amplified using PCR primers which correspond to the 5' and 3' end sequences respectively. The 5' primer containing an EcoRI site and the 3' primer further includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is used to transform bacteria HB101, which are then plated onto agar-containing kanamycin for the purpose of confirming that the vector had the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells are transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product.

5 Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

39
SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: HUMAN GENOME SCIENCES, INC., ET AL.

(ii) TITLE OF INVENTION: G-Protein Coupled Receptor

(iii) NUMBER OF SEQUENCES: 18

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: HUMAN GENOME SCIENCES, INC.

(B) STREET: 9410 KEY WEST AVENUE

(C) CITY: ROCKVILLE

(D) STATE: MARYLAND

(E) COUNTRY: USA

(F) ZIP: 20850

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 INCH DISKETTE

(B) COMPUTER: IBM PS/2

(C) OPERATING SYSTEM: MS-DOS

(D) SOFTWARE: WORD PERFECT 5.1

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/US98/09048

(B) FILING DATE: 07-MAY-1998

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/852,824

(B) FILING DATE: 07-MAY-1997

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: A. ANDERS, BROOKES

(B) REGISTRATION NUMBER: 36,373

(C) REFERENCE/DOCKET NUMBER: PF351PCT.LIC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 301-309-8504

(B) TELEFAX: 301-309-8439

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 2249 BASE PAIRS

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCACGAGGAA CAGAACACTT TCTCATGTCC AGGGTCAGAT TACAAGAGCA CTCAAGACTT 60

TACTGACGAA AACTCAGGAA ATCCTCTATC ACAAAGAGGT TTGGCAACTA AACTAAGACA 120

40

TTAAAAGGAA AATACCAGAT GCCACTCTGC AGGCTGCAAT AACTACTACT TACTGGATAC	180
ATTCAAACCC TCCAGAATCA ACAGTTATCA GGTAACCAAC AAGAA ATG CAA GCC GTC	237
Met Gln Ala Val	
GAC ATT CTC ACC TCT GCG CCT GGG AAC AAC AGT CTG TGC ACC AGA	282
Asp Asn Leu Thr Ser Ala Pro Gly Asn Thr Ser Leu Cys Thr Arg	
5 10 15	
GAC TAC AAA ATC ACC CAG GTC CTC TTC CCA CTG CTC TAC ACT GTC	327
Asp Tyr Lys Ile Thr Gln Val Leu Phe Pro Leu Leu Tyr Thr Val	
20 25 30	
CTG TTT TTT GTT GGA CTT ATC ACA AAT GGC CTG GCG ATG AGG ATT	372
Leu Phe Phe Val Gly Leu Ile Thr Asn Gly Leu Ala Met Arg Ile	
35 40 45	
TTC TTT CAA ATC CGG AGT AAA TCA AAC TTT ATT ATT TTT CTT AAG	417
Phe Phe Gln Ile Arg Ser Lys Ser Asn Phe Ile Ile Phe Leu Lys	
50 55 60	
AAC ACA GTC ATT TCT GAT CTT CTC ATG ATT CTG ACT TTT CCA TTC	462
Asn Thr Val Ile Ser Asp Leu Leu Met Ile Leu Thr Phe Pro Phe	
65 70 75	
AAA ATT CTT AGT GAT GCC AAA CTG GGA ACA GGA CCA CTG AGA ACT	507
Lys Ile Leu Ser Asp Ala Lys Leu Gly Thr Gly Pro Leu Arg Thr	
80 85 90	
TTT GTG TGT CAA GTT ACC TCC GTC ATA TTT TAT TTC ACA ATG TAT	552
Phe Val Cys Gln Val Thr Ser Val Ile Phe Tyr Phe Thr Met Tyr	
95 100 105	
ATC AGT ATT TCA TTC CTG GGA CTG ATA ACT ATC GAT CGC TAC CAG	597
Ile Ser Ile Ser Phe Leu Gly Leu Ile Thr Ile Asp Arg Tyr Gln	
110 115 120	
AAG ACC ACC AGG CCA TTT AAA ACA TCC AAC CCC AAA AAT CTC TTG	642
Lys Thr Thr Arg Pro Phe Lys Thr Ser Asn Pro Lys Asn Leu Leu	
125 130 135	
GGG GCT AAG ATT CTC TCT GTT GTC ATC TGG GCA TTC ATG TTC TTA	687
Gly Ala Lys Ile Leu Ser Val Val Ile Trp Ala Phe Met Phe Leu	
140 145 150	
CTC TCT TTG CCT AAC ATG ATT CTG ACC AAC AGG CAG CCG AGA GAC	732
Leu Ser Leu Pro Asn Met Ile Leu Thr Asn Arg Gln Pro Arg Asp	
155 160 165	
AAG AAT GTG AAG AAA TGC TCT TTC CTT AAA TCA GAG TTC GGT CTA	777
Lys Asn Val Lys Lys Cys Ser Phe Leu Lys Ser Glu Phe Gly Leu	
170 175 180	
GTC TGG CAT GAA ATA GTA AAT TAC ATC TGT CAA GTC ATT TTC TGG	822
Val Trp His Glu Ile Val Asn Tyr Ile Cys Gln Val Ile Phe Trp	
185 190 195	
ATT AAT TTC TTA ATT GTT ATT GTA TGT TAT ACA CTC ATT ACA AAA	867

SUBSTITUTE SHEET (RULE 26)

41

Ile Asn Phe Leu Ile Val Ile Val Cys Tyr Thr Leu Ile Thr Lys	
200 205 210	
GAA CTG TAC CGG TCA TAC GTA AGA ACG AGG GGT GTA GGT AAA GTC	912
Glu Leu Tyr Arg Ser Tyr Val Arg Thr Arg Gly Val Gly Lys Val	
215 220 225	
CCC AGG AAA AAG GTG AAC GTC AAA GTT TTC ATT ATC ATT GCT GTA	957
Pro Arg Lys Lys Val Asn Val Lys Val Phe Ile Ile Ile Ala Val	
230 235 240	
TTC TTT ATT TGT TTT GTT CCT TTC CAT TTT GCC CGA ATT CCT TAC	1002
Phe Phe Ile Cys Phe Val Pro Phe His Phe Ala Arg Ile Pro Tyr	
245 250 255	
ACC CTG AGC CAA ACC CGG GAT GTC TTT GAC TGC ACT GCT GAA AAT	1047
Thr Leu Ser Gln Thr Arg Asp Val Phe Asp Cys Thr Ala Glu Asn	
260 265 270	
ACT CTG TTC TAT GTG AAA GAG AGC ACT CTG TGG TTA ACT TCC TTA	1092
Thr Leu Phe Tyr Val Lys Glu Ser Thr Leu Trp Leu Thr Ser Leu	
275 280 285	
AAT GCA TGC CTG GAT CCG TTC ATC TAT TTT TTC CTT TGC AAG TCC	1137
Asn Ala Cys Leu Asp Pro Phe Ile Tyr Phe Phe Leu Cys Lys Ser	
290 295 300	
TTC AGA AAT TCC TTG ATA AGT ATG CTG AAG TGC CCC AAT TCT GCA	1182
Phe Arg Asn Ser Leu Ile Ser Met Leu Lys Cys Pro Asn Ser Ala	
305 310 315	
ACA TCT CTG TCC CAG GAC AAT AGG AAA AAA GAA CAG GAT GGT GGT	1227
Thr Ser Leu Ser Gln Asp Asn Arg Lys Lys Glu Gln Asp Gly Gly	
320 325 330	
GAC CCA AAT GAA GAG ACT CCA ATG TAA ACAAATTAAC TAAGGAAATA	1274
Asp Pro Asn Glu Glu Thr Pro Met	
335 340	
TTTCAATCTC TTTGTGTTCA GAACTCGTTA AAGCAAAGCG CTAAGTAAAA ATATTAAGTG	1334
ACGAAGAAGC AACTAAGTTA ATAATAATGA CTCTAAAGAA ACAGAAGATT ACAAAGCAA	1394
TTTTCATTTA CCTTTCCAGT ATGAAAAGCT ATCTTAAAT ATAGAAAAGT AATCTAAAGT	1454
GTAGCTGTAT TAGCAGCAAA ACAAACGACA TCCAATTGTC ATGCTGCATG CAAAAGTACA	1514
CAGAATTCAT GTTTTGGCAG AGTTTGGCA AAATGAGTAA TCATATAATA TTTACTGTAA	1574
TTTTTAAAT ACATTATCGT TCACAATTTT ATTTTTCAT AATCAACTAA GGAAGAACGA	1634
TCAATTGGAT ATAATCTTCT TACCAAAAT GATAGTTAAA ATGTATATAT ATCCTAGTCC	1694
CCTAACCAAA TCCTGACCTA TTGGGATACT TATAAAAATT TAAGTAAGTG GGATACACAA	1754
AGAATAATAA CTATTAAGTT TTCATTATTA GCCAAAACC TAAGGGATTT AAATAATTG	1814
AAACTGTATT TGATTGGACT TAATTTTTTA TGTTTATTTA GAAGATAAAG ATTTATAGAA	1874

SUBSTITUTE SHEET (RULE 26)

GACCTTTACA ATAAAGAGAA GAAATATCGA AGTCATTAAA ATAAGGAGAC TTACTTTTAT 1934
 GACATTCTAA TACTAAAAAA TATAGAAATA TTTCTTAAT TCTAGAGAAA CTAGTTTAC 1994
 TAATTTTTTA CAACTTCAAT AATACCATCA CTGACACTTA CCTTTATTAA TTAGCTTCTA 2054
 GAAAATAGCT GCTAATTAGG TTAATGAACA TTTTACCTTA GTGAAAAAAA ATTAATTAAA 2114
 TATGATTACA AAGTTGCACA GCATAACTAC TGAGAGGAAA GTGATTGATC TGTTTGTAAT 2174
 TACTTGTTTG TATTGGTGTG TATAAAATAC AANATTTACA TTAAACTCTA AATCATTAAA 2234
 AAAAAAAAAA AAAAA 2249

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 342 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (C) STRANDEDNESS:
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Gln	Ala	Val	Asp	Asn	Leu	Thr	Ser	Ala	Pro	Gly	Asn	Thr	Ser	5	10	15
Leu	Cys	Thr	Arg	Asp	Tyr	Lys	Ile	Thr	Gln	Val	Leu	Phe	Pro	Leu	20	25	30
Leu	Tyr	Thr	Val	Leu	Phe	Phe	Val	Gly	Leu	Ile	Thr	Asn	Gly	Leu	35	40	45
Ala	Met	Arg	Ile	Phe	Phe	Gln	Ile	Arg	Ser	Lys	Ser	Asn	Phe	Ile	50	55	60
Ile	Phe	Leu	Lys	Asn	Thr	Val	Ile	Ser	Asp	Leu	Leu	Met	Ile	Leu	65	70	75
Thr	Phe	Pro	Phe	Lys	Ile	Leu	Ser	Asp	Ala	Lys	Leu	Gly	Thr	Gly	80	85	90
Pro	Leu	Arg	Thr	Phe	Val	Cys	Gln	Val	Thr	Ser	Val	Ile	Phe	Tyr	95	100	105
Phe	Thr	Met	Tyr	Ile	Ser	Ile	Ser	Phe	Leu	Gly	Leu	Ile	Thr	Ile	110	115	120
Asp	Arg	Tyr	Gln	Lys	Thr	Thr	Arg	Pro	Phe	Lys	Thr	Ser	Asn	Pro	125	130	135
Lys	Asn	Leu	Leu	Gly	Ala	Lys	Ile	Leu	Ser	Val	Val	Ile	Trp	Ala	140	145	150
Phe	Met	Phe	Leu	Leu	Ser	Leu	Pro	Asn	Met	Ile	Leu	Thr	Asn	Arg	155	160	165
Gln	Pro	Arg	Asp	Lys	Asn	Val	Lys	Lys	Cys	Ser	Phe	Leu	Lys	Ser	170	175	180
Glu	Phe	Gly	Leu	Val	Trp	His	Glu	Ile	Val	Asn	Tyr	Ile	Cys	Gln	185	190	195
Val	Ile	Phe	Trp	Ile	Asn	Phe	Leu	Ile	Val	Ile	Val	Cys	Tyr	Thr	200	205	210
Leu	Ile	Thr	Lys	Glu	Leu	Tyr	Arg	Ser	Tyr	Val	Arg	Thr	Arg	Gly	215	220	225

43

Val	Gly	Lys	Val	Pro	Arg	Lys	Lys	Val	Asn	Val	Lys	Val	Phe	Ile	
				230					235					240	
Ile	Ile	Ala	Val	Phe	Phe	Ile	Cys	Phe	Val	Pro	Phe	His	Phe	Ala	
				245					250					255	
Arg	Ile	Pro	Tyr	Thr	Leu	Ser	Gln	Thr	Arg	Asp	Val	Phe	Asp	Cys	
				260					265					270	
Thr	Ala	Glu	Asn	Thr	Leu	Phe	Tyr	Val	Lys	Glu	Ser	Thr	Leu	Trp	
				275					280					285	
Leu	Thr	Ser	Leu	Asn	Ala	Cys	Leu	Asp	Pro	Phe	Ile	Tyr	Phe	Phe	
				290					295					300	
Leu	Cys	Lys	Ser	Phe	Arg	Asn	Ser	Leu	Ile	Ser	Met	Leu	Lys	Cys	
				305					310					315	
Pro	Asn	Ser	Ala	Thr	Ser	Leu	Ser	Gln	Asp	Asn	Arg	Lys	Lys	Glu	
				320					325					330	
Gln	Asp	Gly	Gly	Asp	Pro	Asn	Glu	Glu	Thr	Pro	Met				
				335					340						

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 1737 BASE PAIRS

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

G	GCA	CGA	GCC	CAC	CCT	GCG	TCG	GGC	CTC	AGT	CAG	CCC	CCG	GGG	
Ala	Arg	Ala	His	Pro	Ala	Ser	Gly	Leu	Ser	Gln	Pro	Pro	Gly		43
	-15						-10					-5			
GAG	GCC	ATG	AAC	GCC	ACG	GGG	ACC	CCG	GTG	GCC	CCC	GAG	TCC	TGC	
Glu	Ala	Met	Asn	Ala	Thr	Gly	Thr	Pro	Val	Ala	Pro	Glu	Ser	Cys	88
	1					5					10				
CAA	CAG	CTG	GCG	GCC	GGC	GGG	CAC	AGC	CGG	CTC	ATT	GTT	CTG	CAC	
Gln	Gln	Leu	Ala	Ala	Gly	Gly	His	Ser	Arg	Leu	Ile	Val	Leu	His	133
	15					20					25				
TAC	AAC	CAC	TCG	GGC	CGG	CTG	GCC	GGG	CGC	GGG	GGG	CCG	GAG	GAT	
Tyr	Asn	His	Ser	Gly	Arg	Leu	Ala	Gly	Arg	Gly	Gly	Pro	Glu	Asp	178
	30					35					40				
GGC	GGC	CTG	GGG	GCC	CTG	CGG	GGG	CTG	TCG	GTG	GCC	GCC	AGC	TGC	
Gly	Gly	Leu	Gly	Ala	Leu	Arg	Gly	Leu	Ser	Val	Ala	Ala	Ser	Cys	223
	45					50					55				
CTG	GTG	GTG	CTG	GAG	AAC	TTG	CTG	GTG	CTG	GCG	GCC	ATC	ACC	AGC	
Leu	Val	Val	Leu	Glu	Asn	Leu	Leu	Val	Leu	Ala	Ala	Ile	Thr	Ser	268
	60					65					70				
CAC	ATG	CGG	TCG	CAA	CGC	TGG	GTC	TAC	TAT	TGC	CTG	GTG	AAC	ATT	
His	Met	Arg	Ser	Gln	Arg	Trp	Val	Tyr	Tyr	Cys	Leu	Val	Asn	Ile	313
	75					80					85				

SUBSTITUTE SHEET (RULE 26)

ACG ATG AGT GAC CTG CTC ACG GGC GCG GCC TAC CTG GCC AAC GTG	358
Thr Met Ser Asp Leu Leu Thr Gly Ala Ala Tyr Leu Ala Asn Val	
90 95 100	
CTG CTG TCG GGG GCC CGC ACC TTC CGT CTG GCG CCC GCC CAG TGG	403
Leu Leu Ser Gly Ala Arg Thr Phe Arg Leu Ala Pro Ala Gln Trp	
105 110 115	
TTC CTA CGG AAG GGC CTG CTC TTC ACC GCC CTG GCC GCC TCC ACC	448
Phe Leu Arg Lys Gly Leu Leu Phe Thr Ala Leu Ala Ala Ser Thr	
120 125 130	
TTC AGC CTG CTC TTC ACT GCA GGG TTG CGC TTT GCC ACC ATG GTG	493
Phe Ser Leu Leu Phe Thr Ala Gly Leu Arg Phe Ala Thr Met Val	
135 140 145	
CGG CCG GTG GCC GAG AGC GGG GCC ACC AAG ACC AGC CGC GTC TAC	538
Arg Pro Val Ala Glu Ser Gly Ala Thr Lys Thr Ser Arg Val Tyr	
150 155 160	
GGC TTC ATC GGC CTC TGC TGG CTG CTG GCC GCG CTG CTG GGG ATG	583
Gly Phe Ile Gly Leu Cys Trp Leu Leu Ala Ala Leu Leu Gly Met	
165 170 175	
CTG CCT TTG CTG GGC TGG AAC TGC CTG TGC GCC TTT GAC CGC TGC	628
Leu Pro Leu Leu Gly Trp Asn Cys Leu Cys Ala Phe Asn Arg Cys	
180 185 190	
TCC AGC CTT CTG CCC CTC TAC TCC AAG CGC TAC ATC CTC TTC TGC	673
Ser Ser Leu Leu Pro Leu Tyr Ser Arg Arg Thr Ile Leu Phe Cys	
195 200 205	
CTG GTG ATC TTC GCC GGC GTC CTG GCC ACC ATC ATG GGC CTC TAT	718
Leu Val Ile Phe Ala Gly Val Leu Ala Thr Ile Met Gly Leu Tyr	
210 215 220	
GGG GCC ATC TTC CGC CTG GTG CAG GCC AGC GGG CAG AAG GCC CCA	763
Gly Ala Ile Phe Arg Leu Val Gln Ala Ser Gly Gln Lys Ala Pro	
225 230 235	
CGC CCA GCG GCC CGC CGC AAG GCC CGC CGC CTG CTG AAG ACG GTG	808
Arg Pro Ala Ala Arg Arg Lys Ala Arg Arg Leu Leu Lys Thr Val	
240 245 250	
CTG ATG ATC CTG CTG GCC TCC TAG GTGTGCTGGG GACCACTCTT CGGGCTGCTG	862
Leu Met Ile Leu Leu Ala Ser	
255 260	
CTGGCCGACG TCTTTGGCTC CAACCTCTGG GCCCAGGAGT ACCTGCGGGG CATGGACTGG	922
ATCCTGGCCC TGGCCGTCCT CAACTCGGCG GTCAACCCCA TCATCTACTC CTTCCGCAGC	982
AGGGAGGTGT GCAGAGCCGT GCTCAGCTTC CTCTGCTGCG GGTGTCTCCG GCTGGGCATG	1042
CGAGGGCCCCG GGGACTGCCT GGCCCGGGCC GTCGAGGCTC ACTCCGGAGC TTCCACCACC	1102

45

GACAGCTCTC TGAGGCCAAG GGACAGCTTT CGCGGCTCCC GCTCGCTCAG CTTTCGGATG 1162
 CGGGAGCCCC TGTCCAGCAT CTCCAGCGTG CGGAGCATCT GAAGTTGCAG TCTTGCGTGT 1222
 GGATGGTGCA ACCACCGGGT GCGTGCCAGG CAGGCCCTCC TGGGGTACAG GAAGCTGTGT 1282
 GCACGCAACC TCGCCCTGTA TGGGGAGCAG GGAACGGGAC AGGCCCCCAT GGAAGCTGTGT 1342
 GGTGGCCTCT CGGGGCTTCT GACGCCATAT GGAAGCTGTGT ATTGCCTATG GCTCACCTGT 1402
 GACAAGGAGG CAACCACCCC ACCTCCCCGT AGGAGCAGAG AGCACCTTGG TGTGGGGGCG 1462
 AGTGGGTTCC CCACAACCCC GCTTCTGTGT GATTCTGGGG AAGTCCCGGC CCCTCTCTGG 1522
 GCCTCAGTAG GGCTCCCAGG CTGCAAGGGG TGGACTGTGG GATGCATGCC CTGGCAACAT 1682
 TGAAGTTCGA TCATGGTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAA 1737

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 276 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (C) STRANDEDNESS:
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ala	Arg	Ala	His	Pro	Ala	Ser	Gly	Leu	Ser	Gln	Pro	Pro	Gly	Glu
-15						-10					-5			
Ala	Met	Asn	Ala	Thr	Gly	Thr	Pro	Val	Ala	Pro	Glu	Ser	Cys	Gln
1					5					10				
Gln	Leu	Ala	Ala	Gly	Gly	His	Ser	Arg	Leu	Ile	Val	Leu	His	Tyr
15					20					25				
Asn	His	Ser	Gly	Arg	Leu	Ala	Gly	Arg	Gly	Gly	Pro	Glu	Asp	Gly
30					35					40				
Gly	Leu	Gly	Ala	Leu	Arg	Gly	Leu	Ser	Val	Ala	Ala	Ser	Cys	Leu
45					50					55				
Val	Val	Leu	Glu	Asn	Leu	Leu	Val	Leu	Ala	Ala	Ile	Thr	Ser	His
60					65					70				
Met	Arg	Ser	Gln	Arg	Trp	Val	Tyr	Tyr	Cys	Leu	Val	Asn	Ile	Thr
75					80					85				
Met	Ser	Asp	Leu	Leu	Thr	Gly	Ala	Ala	Tyr	Leu	Ala	Asn	Val	Leu
90					95					100				
Leu	Ser	Gly	Ala	Arg	Thr	Phe	Arg	Leu	Ala	Pro	Ala	Gln	Trp	Phe
105					110					115				
Leu	Arg	Lys	Gly	Leu	Leu	Phe	Thr	Ala	Leu	Ala	Ala	Ser	Thr	Phe
120					125					130				
Ser	Leu	Leu	Phe	Thr	Ala	Gly	Leu	Arg	Phe	Ala	Thr	Met	Val	Arg
135					140					145				
Pro	Val	Ala	Glu	Ser	Gly	Ala	Thr	Lys	Thr	Ser	Arg	Val	Tyr	Gly
150					155					160				
Phe	Ile	Gly	Leu	Cys	Trp	Leu	Leu	Ala	Ala	Leu	Leu	Gly	Met	Leu
165					170					175				
Pro	Leu	Leu	Gly	Trp	Asn	Cys	Leu	Cys	Ala	Phe	Asn	Arg	Cys	Ser

SUBSTITUTE SHEET (RULE 26)

46

180	185	190
Ser Leu Leu Pro Leu Tyr Ser Arg Arg Thr	Ile Leu Phe Cys Leu	
195	200	205
Val Ile Phe Ala Gly Val Leu Ala Thr Ile	Met Gly Leu Tyr Gly	
210	215	220
Ala Ile Phe Arg Leu Val Gln Ala Ser Gly	Gln Lys Ala Pro Arg	
225	230	235
Pro Ala Ala Arg Arg Lys Ala Arg Arg Leu	Leu Lys Thr Val Leu	
240	245	250
Met Ile Leu Leu Ala Ser		
255	260	

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 28 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGAGGATCC ATGCAAGCCG TCGACAAT

28

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 28 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCGAGGATCC TTACATTGGA GTCTCTTC

28

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 34 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCGAGGATCC GCCATCATGC AAGCCGTCGA CAAT

34

47

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 28 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCGAGGATCC TTACATTGGA GTCTCTTC

28

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 34 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CCGAGGATCC GCCATCATGC AAGCCGTCGA CAAT

34

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 55 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCGATCTAGA TTAATCCCAT ACGACGTCCC AGACTACGCT CATTGGAGTC TCTTC

55

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 28 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCGAGGATCC ATGAACGCCA CGGGGACC

28

SUBSTITUTE SHEET (RULE 26)

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 28 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: Oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCGAGGATCC TCAGATGCTC CGCACGCT

28

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 34 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: Oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCGAGGATCC GCCATCATGA ACGCCACGGG GACC

34

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 28 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: Oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCGAGGATCC TCAGATGCTC CGCACGCT

28

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 34 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: Oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCGAGGATCC GCCATCATGA ACGCCACGGG GACC

34

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 55 BASE PAIRS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCGATCTAGA TCAATCCCAT ACGACGTCCC AGACTACGCT GATGCTCCGC ACGCT

55

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 348 AMINO ACIDS
 - (B) TYPE: AMINO ACID
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Ile	Gln	Met	Ala	Asn	Asn	Phe	Thr	Pro	Pro	Ser	Ala	Thr	Pro	Gln	5	10	15
Asn	Asp	Cys	Asp	Leu	Tyr	Ala	His	His	Ser	Thr	Ala	Arg	Ile	Val	20	25	30
Met	Pro	Leu	His	Tyr	Ser	Leu	Val	Phe	Ile	Ile	Gly	Leu	Val	Gly	35	40	45
Asn	Leu	Leu	Ala	Leu	Val	Val	Ile	Val	Gln	Asn	Arg	Lys	Lys	Ile	50	55	60
Asn	Ser	Thr	Thr	Leu	Tyr	Ser	Thr	Asn	Leu	Val	Ile	Ser	Asp	Ile	65	70	75
Leu	Phe	Thr	Thr	Ala	Leu	Pro	Thr	Arg	Ile	Ala	Tyr	Tyr	Ala	Met	80	85	90
Gly	Phe	Asp	Trp	Arg	Ile	Gly	Asp	Ala	Leu	Cys	Arg	Ile	Thr	Ala	95	100	105
Leu	Val	Phe	Tyr	Ile	Asn	Thr	Tyr	Ala	Gly	Val	Asn	Phe	Met	Thr	110	115	120
Cys	Leu	Ser	Ile	Asp	Arg	Phe	Ile	Ala	Val	Val	His	Pro	Leu	Arg	125	130	135
Tyr	Asn	Lys	Ile	Lys	Arg	Ile	Glu	His	Ala	Lys	Gly	Val	Cys	Ile	140	145	150
Phe	Val	Trp	Ile	Leu	Val	Phe	Ala	Gln	Thr	Leu	Pro	Leu	Leu	Ile	155	160	165
Asn	Pro	Met	Ser	Lys	Gln	Glu	Ala	Glu	Arg	Ile	Thr	Cys	Met	Glu	170	175	180
Tyr	Pro	Asn	Phe	Glu	Glu	Thr	Lys	Ser	Leu	Pro	Trp	Ile	Leu	Leu	185	190	195
Gly	Ala	Cys	Phe	Ile	Gly	Tyr	Val	Leu	Pro	Leu	Ile	Ile	Ile	Lys			

	200	50	205	210
Ile Cys Tyr Ser	Gln Ile Cys Cys Lys	Leu Phe Arg Thr	Ala Lys	
	215	220	225	
Gln Asn Pro Leu	Thr Glu Lys Ser Gly	Val Asn Lys Lys	Ala Leu	
	230	235	240	
Asn Thr Ile Ile	Leu Ile Ile Val Val	Phe Val Leu Cys	Phe Thr	
	245	250	255	
Pro Tyr His Val	Ala Ile Ile Gln His	Met Ile Lys Lys	Leu Arg	
	260	265	270	
Phe Ser Asn Phe	Leu Glu Cys Ser Gln	Arg His Ser Phe	Gln Ile	
	275	280	285	
Ser Leu His Phe	Thr Val Cys Leu Met	Asn Phe Asn Cys	Cys Met	
	290	295	300	
Asp Pro Phe Ile	Tyr Phe Phe Ala Cys	Lys Gly Tyr Lys	Arg Lys	
	305	310	315	
Val Met Arg Met	Leu Lys Arg Gln Val	Ser Val Ser Ile	Ser Ser	
	320	325	330	
Ala Val Lys Ser	Ala Pro Glu Glu Asn	Ser Arg Glu Met	Thr Glu	
	335	340	345	
Thr Gln Met				

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 381 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (C) STRANDEDNESS:
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met Gly Pro Thr	Ser Val Pro Leu	Val Lys Ala His	Arg Ser Ser
5	10	15	
Val Ser Asp Tyr	Val Asn Tyr Asp	Ile Ile Val Arg	His Tyr Asn
20	25	30	
Tyr Thr Gly Lys	Leu Asn Ile Ser	Ala Asp Lys	Glu Asn Ser Ile
35	40	45	
Lys Leu Thr Ser	Val Val Phe Ile	Leu Ile Cys	Cys Phe Ile Ile
50	55	60	
Leu Glu Asn Ile	Phe Val Leu Leu	Thr Ile Trp	Lys Thr Lys Lys
65	70	75	
Phe His Arg Pro	Met Tyr Tyr Phe	Ile Gly Asn	Leu Ala Leu Ser
80	85	90	
Asp Leu Leu Ala	Gly Val Ala Tyr	Thr Ala Asn	Leu Leu Leu Ser
95	100	105	
Gly Ala Thr Thr	Tyr Lys Leu Thr	Pro Ala Gln	Trp Phe Leu Arg
110	115	120	
Glu Gly Ser Met	Phe Val Ala Leu	Ser Ala Ser	Val Phe Ser Leu
125	130	135	
Leu Ala Ile Ala	Ile Glu Arg Tyr	Ile Thr Met	Leu Lys Met Lys
140	145	150	
Leu His Asn Gly	Ser Asn Asn Phe	Arg Leu Phe	Leu Leu Ile Ser
155	160	165	
Ala Cys Trp Val	Ile Ser Leu Ile	Leu Gly Gly	Leu Pro Ile Met
170	175	180	

51

Gly Trp Asn Cys Ile Ser Ala Leu Ser	Ser Cys Ser Thr Val Leu
185	190 195
Pro Leu Tyr His Lys His Tyr Ile Leu	Phe Cys Thr Thr Val Phe
200	205 210
Thr Leu Leu Leu Leu Ser Ile Val Ile	Leu Tyr Cys Arg Ile Tyr
215	220 225
Ser Leu Val Arg Thr Arg Ser Arg Arg	Leu Thr Phe Arg Lys Asn
230	235 240
Ile Ser Lys Ala Ser Arg Ser Ser Glu	Asn Val Ala Leu Leu Lys
245	250 255
Thr Val Ile Ile Val Leu Ser Val Phe	Ile Ala Cys Trp Ala Pro
260	265 270
Leu Phe Ile Leu Leu Leu Leu Asp Val	Gly Cys Lys Val Lys Thr
275	280 285
Cys Asp Ile Leu Phe Arg Ala Glu Tyr	Phe Leu Val Leu Ala Val
290	295 300
Leu Asn Ser Gly Thr Asn Pro Ile Ile	Tyr Thr Leu Thr Asn Lys
305	310 315
Glu Met Arg Arg Ala Phe Ile Arg Ile	Met Ser Cys Cys Lys Cys
320	325 330
Pro Ser Gly Asp Ser Ala Gly Lys Phe	Lys Arg Pro Ile Ile Ala
335	340 345
Gly Met Glu Phe Ser Arg Ser Lys Ser	Asp Asn Ser Ser His Pro
350	355 360
Gln Lys Asp Glu Gly Asp Asn Pro Glu	Thr Ile met Ser Ser Gly
365	370 375
Asn Val Asn Ser Ser Ser	
380	

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> . line <u>17</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <u> </u>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit <u>April 28, 1997</u>	Accession Number <u>209004</u>
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i>	
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number or Deposit")	
<div style="text-align: center;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><input type="checkbox"/> This sheet was received with the international application</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;">Authorized officer</div>	<div style="text-align: center;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;">Authorized officer</div>

SUBSTITUTE SHEET (RULE 26)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

A. The indications made below relate to the microorganism referred to in the description on page <u>8</u> , line <u>2</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <u>---</u>	
Name of depositary institution <div style="text-align: center;">American Type Culture Collection</div>	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit April 28, 1997	Accession Number 209003
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> This information is continued on an additional sheet	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i>	
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>	
The indications listed below will be submitted to the International Bureau later <i>(specify the general nature of the indications, e.g., "Accession Number of Deposit")</i>	
<div style="text-align: center;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><input type="checkbox"/> This sheet was received with the international application</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;">Authorized officer</div>	<div style="text-align: center;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><input type="checkbox"/> This sheet was received by the International Bureau on</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;">Authorized officer</div>

SUBSTITUTE SHEET (RULE 26)

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of:
 - (a) a polynucleotide encoding a polypeptide comprising amino acids 2 to 342 of SEQ ID NO:2;
 - (b) a polynucleotide encoding a polypeptide comprising amino acids 1 to 260 of SEQ ID NO:4; and
 - (c) the complement of (a) or (b).
2. The isolated polynucleotide of claim 1 wherein said member is (a).
3. The isolated polynucleotide of claim 1 wherein said member is (b).
4. The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.
4. The isolated polynucleotide of claim 1, wherein said polynucleotide is RNA.
5. A method of making a recombinant vector comprising inserting the isolated polynucleotide of claim 1 into a vector, wherein said polynucleotide is DNA.
6. A recombinant vector comprising the polynucleotide of claim 1, wherein said polynucleotide is DNA.
7. A recombinant host cell comprising the polynucleotide of claim 1, wherein said polynucleotide is DNA.
8. A method for producing a polypeptide comprising expressing from the recombinant cell of claim 11 the polypeptide encoded by said polynucleotide.

9. The isolated polynucleotide of claim 1 comprising a polynucleotide, which includes nucleotides 226 to 1251 of SEQ ID NO:1.
10. The isolated polynucleotide of claim 1 comprising a polynucleotide, which includes nucleotides 2 to 827 of SEQ ID NO:3.
11. An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of:
- (a) a polynucleotide encoding the same polypeptide encoded by the human cDNA in ATCC Deposit No. 209003;
 - (b) a polynucleotide encoding the same polypeptide encoded by the human cDNA in ATCC Deposit No. 209004; and
 - (c) the complement of (a) or (b).
12. The isolated polynucleotide of claim 17, wherein the member is (a).
13. The isolated polynucleotide of claim 17, wherein the member is (b).
14. A method of making a recombinant vector comprising inserting the isolated polynucleotide of claim 11 into a vector, wherein said polynucleotide is DNA.
15. A recombinant vector comprising the polynucleotide of claim 11, wherein said polynucleotide is DNA.
16. A recombinant host cell comprising the polynucleotide of claim 11, wherein said polynucleotide is DNA.
17. A method for producing a polypeptide comprising expressing from the recombinant cell of claim 16 the polypeptide encoded by said polynucleotide.
18. An isolated polypeptide comprising:

56

a mature polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to member selected from the group consisting of:

- (a) a polynucleotide encoding a polypeptide comprising amino acids 2 to 342 of SEQ ID NO:2;
- (b) a polynucleotide encoding a polypeptide comprising amino acids 1 to 260 of SEQ ID NO:4; and
- (c) the complement of (a) or (b).

- 19. An antibody against the polypeptide of claim 18.
- 20. An antagonist against the polypeptide of claim 18.
- 21. A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 18 comprising:
 - determining a mutation in a nucleic acid sequence encoding said polypeptide.

1/7

GCACGAGGAA CAGAACACTT TCTCATGTCC AGGGTCAGAT TACAAGAGCA CTCAAGACTT 60
TACTGACGAA AACTCAGGAA ATCCTCTATC ACAAAGAGGT TTGGCAACTA AACTAAGACA 120
TTAAAAGGAA AATACCAGAT GCCACTCTGC AGGCTGCAAT AACTACTACT TACTGGATAC 180
ATTCAAACCC TCCAGAATCA ACAGTTATCA GGTAACCAAC AAGAA ATG CAA GCC GTC 237
Met Gln Ala Val

GAC ATT CTC ACC TCT GCG CCT GGG AAC AAC AGT CTG TGC ACC AGA 282
Asp Asn Leu Thr Ser Ala Pro Gly Asn Thr Ser Leu Cys Thr Arg
5 10 15

GAC TAC AAA ATC ACC CAG GTC CTC TTC CCA CTG CTC TAC ACT GTC 327
Asp Tyr Lys Ile Thr Gln Val Leu Phe Pro Leu Leu Tyr Thr Val
20 25 30

CTG TTT TTT GTT GGA CTT ATC ACA AAT GGC CTG GCG ATG AGG ATT 372
Leu Phe Phe Val Gly Leu Ile Thr Asn Gly Leu Ala Met Arg Ile
35 40 45

TTC TTT CAA ATC CGG AGT AAA TCA AAC TTT ATT ATT TTT CTT AAG 417
Phe Phe Gln Ile Arg Ser Lys Ser Asn Phe Ile Ile Phe Leu Lys
50 55 60

AAC ACA GTC ATT TCT GAT CTT CTC ATG ATT CTG ACT TTT CCA TTC 462
Asn Thr Val Ile Ser Asp Leu Leu Met Ile Leu Thr Phe Pro Phe
65 70 75

AAA ATT CTT AGT GAT GCC AAA CTG GGA ACA GGA CCA CTG AGA ACT 507
Lys Ile Leu Ser Asp Ala Lys Leu Gly Thr Gly Pro Leu Arg Thr
80 85 90

TTT GTG TGT CAA GTT ACC TCC GTC ATA TTT TAT TTC ACA ATG TAT 552
Phe Val Cys Gln Val Thr Ser Val Ile Phe Tyr Phe Thr Met Tyr
95 100 105

ATC AGT ATT TCA TTC CTG GGA CTG ATA ACT ATC GAT CGC TAC CAG 597
Ile Ser Ile Ser Phe Leu Gly Leu Ile Thr Ile Asp Arg Tyr Gln
110 115 120

AAG ACC ACC AGG CCA TTT AAA ACA TCC AAC CCC AAA AAT CTC TTG 642
Lys Thr Thr Arg Pro Phe Lys Thr Ser Asn Pro Lys Asn Leu Leu
125 130 135

GGG GCT AAG ATT CTC TCT GTT GTC ATC TGG GCA TTC ATG TTC TTA 687
Gly Ala Lys Ile Leu Ser Val Val Ile Trp Ala Phe Met Phe Leu
140 145 150

CTC TCT TTG CCT AAC ATG ATT CTG ACC AAC AGG CAG CCG AGA GAC 732
Leu Ser Leu Pro Asn Met Ile Leu Thr Asn Arg Gln Pro Arg Asp
155 160 165

AAG AAT GTG AAG AAA TGC TCT TTC CTT AAA TCA GAG TTC GGT CTA 777
Lys Asn Val Lys Lys Cys Ser Phe Leu Lys Ser Glu Phe Gly Leu
170 175 180

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/7

GTC Val 185	TGG Trp	CAT His	GAA Glu	ATA Ile	GTA Val 190	AAT Asn	TAC Tyr	ATC Ile	TGT Cys	CAA Gln 195	GTC Val	ATT Ile	TTC Phe	TGG Trp	822
ATT Ile 200	AAT Asn	TTC Phe	TTA Leu	ATT Ile	GTT Val 205	ATT Ile	GTA Val	TGT Cys	TAT Tyr	ACA Thr 210	CTC Leu	ATT Ile	ACA Thr	AAA Lys	867
GAA Glu 215	CTG Leu	TAC Tyr	CGG Arg	TCA Ser	TAC Tyr 220	GTA Val	AGA Arg	ACG Thr	AGG Arg	GGT Gly 225	GTA Val	GGT Gly	AAA Lys	GTC Val	912
CCC Pro 230	AGG Arg	AAA Lys	AAG Lys	GTG Val	AAC Asn 235	GTC Val	AAA Lys	GTT Val	TTC Phe	ATT Ile 240	ATC Ile	ATT Ile	GCT Ala	GTA Val	957
TTC Phe 245	TTT Phe	ATT Ile	TGT Cys	TTT Phe	GTT Val 250	CCT Pro	TTC Phe	CAT His	TTT Phe	GCC Ala 255	CGA Arg	ATT Ile	CCT Pro	TAC Tyr	1002
ACC Thr 260	CTG Leu	AGC Ser	CAA Gln	ACC Thr	CGG Arg 265	GAT Asp	GTC Val	TTT Phe	GAC Asp	TGC Cys 270	ACT Thr	GCT Ala	GAA Glu	AAT Asn	1047
ACT Thr 275	CTG Leu	TTC Phe	TAT Tyr	GTG Val	AAA Lys 280	GAG Glu	AGC Ser	ACT Thr	CTG Leu	TGG Trp 285	TTA Leu	ACT Thr	TCC Ser	TTA Leu	1092
AAT Asn 290	GCA Ala	TGC Cys	CTG Leu	GAT Asp	CCG Pro 295	TTC Phe	ATC Ile	TAT Tyr	TTT Phe	TTC Phe 300	CTT Leu	TGC Cys	AAG Lys	TCC Ser	1137
TTC Phe 305	AGA Arg	AAT Asn	TCC Ser	TTG Leu	ATA Ile 310	AGT Ser	ATG Met	CTG Leu	AAG Lys	TGC Cys 315	CCC Pro	AAT Asn	TCT Ser	GCA Ala	1182
ACA Thr 320	TCT Ser	CTG Leu	TCC Ser	CAG Gln	GAC Asp 325	AAT Asn	AGG Arg	AAA Lys	AAA Lys	GAA Glu 330	CAG Gln	GAT Asp	GGT Gly	GGT Gly	1227
GAC Asp 335	CCA Pro	AAT Asn	GAA Glu	GAG Glu	ACT Thr 340	CCA Pro	ATG Met	TAA	ACAAATTAAC	TAAGGAAATA					1274
TTTCAATCTC	TTTGTGTTCA	GAAGCTCGTTA	AAGCAAAGCG	CTAAGTAAAA	ATATTAAGT	1334									
ACGAAGAAGC	AACTAAGTTA	ATAATAATGA	CTCTAAAGAA	ACAGAAGATT	ACAAAAGCAA	1394									
TTTTCAATTTA	CCTTTCCAGT	ATGAAAAGCT	ATCTTAAAT	ATAGAAAAGT	AATCTAAAGT	1454									
GTAGCTGTAT	TAGCAGCAAA	ACAAACGACA	TCCAATTGTC	ATGCTGCATG	CAAACTACA	1514									
CAGAATTCAT	GTTTTGGCAG	AGTTTTGGCA	AAATGAGTAA	TCATATAATA	TTTACTGTAA	1574									
TTTTTAAAT	ACATTATCGT	TCACAATTTT	ATTTTTTCAT	AATCAACTAA	GGAAGAACGA	1634									
TCAATTGGAT	ATAATCTTCT	TACCAAAAAT	GATAGTTAAA	ATGTATATAT	ATCCTAGTCC	1694									

FIG. 1 B

SUBSTITUTE SHEET (RULE 26)

3/7

CCTAACCAAA TCCTGACCTA TTGGGATACT TATAAAAATT TAAGTAAGTG GGATACACAA 1754
AGAATAATAA CTATTAACCTT TTCATTATTA GCCAAAAACC TAAGGGATTT AAACCTAATTG 1814
AAACTGTATT TGATTGGACT TAATTTTTTTA TGTTTATTTA GAAGATAAAG ATTTATAGAA 1874
GACCTTTACA ATAAAGAGAA GAAATATCGA AGTCATTAAA ATAAGGAGAC TTACTTTTAT 1934
GACATTCTAA TACTTAAAAA TATAGAAATA TTTCTTAAT TCTAGAGAAA CTAGTTTTTAC 1994
TAATTTTTTTA CAACTTCAAT AATACCATCA CTGACACTTA CCTTTATTAA TTAGCTTCTA 2054
GAAAATAGCT GCTAATTAGG TTAATGAACA TTTTACCTTA GTGAAAAAAAA ATTAATTAAA 2114
TATGATTACA AAGTTGCACA GCATAACTAC TGAGAGGAAA GTGATTGATC TGTTTGTAAT 2174
TACTTGTTTG TATTGGTGTG TATAAAATAC AAXATTTACA TTAACTCTA AATCATTTAA 2234
AAAAAAAAAA AAAAA 2249

FIG. 1C

```

1 MQAVDNLTSAP...GNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLA 46
  :|.:|:|.:. ||.: .....::||.|.:|:|:|. | ||
3 IQMANNFTPPSATPQGNDCLYAAHSTARIVMPLHYSLVFIIIGLVGNLLA 52

47 MRIF FQIRSKSN.FIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTF 95
  :.:| |.| | .:. | |||:|:..:| :| |. .:.
53 LVVIVQNRRKINSTTLYSTNVLISDILFTTALPTRIAYYAMGFDWRIGDA 102

96 VCQVTSVIFYFTMYISISFLGLITIDRYQKTTRPFKTSNPKNLLGAKILS 145
  :|.:|:|:|:|. |.:|:|.:.|||: ..:|:~. |.: ||.:
103 LCRITALVFYINTYAGVNFMTCLSIDRFIAVVHPLRYNKIKRIEHAKGVC 152

146 VVIWAFMFLLSLPNMI..LTNRQPRDKNVKKCSFLKSEFGLVWHEIVNYI 193
  :.:| :.:| .|| :| :..... :..... :. |. :....
153 IFVWILVFAQTLPLLINPMSKQEERITCMEYPNFEETKSLPWILLGACF 202

194 CQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGK..VPRKKVNVKVFII 241
  .. :. :.:|:~:|:|. |. |:|. ... :.| ]:| :|. :.:|
203 IGYVL..PLIIILICYSQICCKLFR TAKQNPLETKSGVNKKALNTIILII 250

242 IAVFFICFVPFH FARIPYTLSQTR..DVFDCTAENTLFYVKESTLWL TSL 289
  : ||.:|||. |:|. | |.. :. | :.:|:~. :.: . | :| :.
251 V.VFVLCFTP YHVAIIQHMIKKLRFSNFLECSQRHSFQISLHFTVCLMN F 299

290 NACLDPFIYFFLCKSF RNSLISMLKCPNSATSLSQDNRKKEODGGDPNEE 339
  |.:|:|:|:|:| |:~:~:~:|:| |. |.:| :. :. :.:~. |.
300 NCCMDPFIYFFACKGYKRKV MRMLKRVVS.VSISSAVKS APEENSREMTE 348

340 TPM 342
  |.|
349 TQM 351
```

SUBSTITUTE SHEET (RULE 26)

5/7

G	GCA	CGA	GCC	CAC	CCT	GCG	TCG	GGC	CTC	AGT	CAG	CCC	CCG	GGG	43
	Ala	Arg	Ala	His	Pro	Ala	Ser	Gly	Leu	Ser	Gln	Pro	Pro	Gly	
		-15					-10					-5			
GAG	GCC	ATG	AAC	GCC	ACG	GGG	ACC	CCG	GTG	GCC	CCC	GAG	TCC	TGC	88
Glu	Ala	Met	Asn	Ala	Thr	Gly	Thr	Pro	Val	Ala	Pro	Glu	Ser	Cys	
		1				5					10				
CAA	CAG	CTG	GCG	GCC	GGC	GGG	CAC	AGC	CGG	CTC	ATT	GTT	CTG	CAC	131
Gln	Gln	Leu	Ala	Ala	Gly	Gly	His	Ser	Arg	Leu	Ile	Val	Leu	His	
	15					20					25				
TAC	AAC	CAC	TCG	GGC	CGG	CTG	GCC	GGG	CGC	GGG	GGG	CCG	GAG	GAT	176
Tyr	Asn	His	Ser	Gly	Arg	Leu	Ala	Gly	Arg	Gly	Gly	Pro	Glu	Asp	
	30					35					40				
GGC	GGC	CTG	GGG	GCC	CTG	CGG	GGG	CTG	TCG	GTG	GCC	GCC	AGC	TGC	221
Gly	Gly	Leu	Gly	Ala	Leu	Arg	Gly	Leu	Ser	Val	Ala	Ala	Ser	Cys	
	45					50					55				
CTG	GTG	GTG	CTG	GAG	AAC	TTG	CTG	GTG	CTG	GCG	GCC	ATC	ACC	AGC	266
Leu	Val	Val	Leu	Glu	Asn	Leu	Leu	Val	Leu	Ala	Ala	Ile	Thr	Ser	
	60					65					70				
CAC	ATG	CGG	TCG	CAA	CGC	TGG	GTC	TAC	TAT	TGC	CTG	GTG	AAC	ATT	311
His	Met	Arg	Ser	Gln	Arg	Trp	Val	Tyr	Tyr	Cys	Leu	Val	Asn	Ile	
	75					80					85				
ACG	ATG	AGT	GAC	CTG	CTC	ACG	GGC	GCG	GCC	TAC	CTG	GCC	AAC	GTG	356
Thr	Met	Ser	Asp	Leu	Leu	Thr	Gly	Ala	Ala	Tyr	Leu	Ala	Asn	Val	
	90					95					100				
CTG	CTG	TCG	GGG	GCC	CGC	ACC	TTC	CGT	CTG	GCG	CCC	GCC	CAG	TGG	401
Leu	Leu	Ser	Gly	Ala	Arg	Thr	Phe	Arg	Leu	Ala	Pro	Ala	Gln	Trp	
	105					110					115				
TTC	CTA	CGG	AAG	GGC	CTG	CTC	TTC	ACC	GCC	CTG	GCC	GCC	TCC	ACC	446
Phe	Leu	Arg	Lys	Gly	Leu	Leu	Phe	Thr	Ala	Leu	Ala	Ala	Ser	Thr	
	120					125					130				
TTC	AGC	CTG	CTC	TTC	ACT	GCA	GGG	TTG	CGC	TTT	GCC	ACC	ATG	GTG	491
Phe	Ser	Leu	Leu	Phe	Thr	Ala	Gly	Leu	Arg	Phe	Ala	Thr	Met	Val	
	135					140					145				
CGG	CCG	GTG	GCC	GAG	AGC	GGG	GCC	ACC	AAG	ACC	AGC	CGC	GTC	TAC	536
Arg	Pro	Val	Ala	Glu	Ser	Gly	Ala	Thr	Lys	Thr	Ser	Arg	Val	Tyr	
	150					155					160				
GGC	TTC	ATC	GGC	CTC	TGC	TGG	CTG	CTG	GCC	GCG	CTG	CTG	GGG	ATG	581
Gly	Phe	Ile	Gly	Leu	Cys	Trp	Leu	Leu	Ala	Ala	Leu	Leu	Gly	Met	
	165					170					175				
CTG	CCT	TTG	CTG	GGC	TGG	AAC	TGC	CTG	TGC	GCC	TTT	GAC	CGC	TGC	626
Leu	Pro	Leu	Leu	Gly	Trp	Asn	Cys	Leu	Cys	Ala	Phe	Asn	Arg	Cys	
	180					185					190				

FIG.3A

6/7

TCC AGC CTT CTG CCC CTC TAC TCC AAG CGC TAC ATC CTC TTC TGC Ser Ser Leu Leu Pro Leu Tyr Ser Arg Arg Thr Ile Leu Phe Cys 195 200 205	671
CTG GTG ATC TTC GCC GGC GTC CTG GCC ACC ATC ATG GGC CTC TAT Leu Val Ile Phe Ala Gly Val Leu Ala Thr Ile Met Gly Leu Tyr 210 215 220	716
GGG GCC ATC TTC CGC CTG GTG CAG GCC AGC GGG CAG AAG GCC CCA Gly Ala Ile Phe Arg Leu Val Gln Ala Ser Gly Gln Lys Ala Pro 225 230 235	761
CGC CCA GCG GCC CGC CGC AAG GCC CGC CGC CTG CTG AAG ACG GTG Arg Pro Ala Ala Arg Arg Lys Ala Arg Arg Leu Leu Lys Thr Val 240 245 250	806
CTG ATG ATC CTG CTG GCC TCC TAG GTGTGCTGGG GACCACTCTT CGGGCTGCTG Leu Met Ile Leu Leu Ala Ser 255 260	860
CTGGCCGACG TCTTTGGCTC CAACCTCTGG GCCCAGGAGT ACCTGCGGGG CATGGACTGG	920
ATCCTGGCCC TGGCCGTCCT CAACTCGGCG GTCAACCCCA TCATCTACTC CTTCCGCAGC	980
AGGGAGGTGT GCAGAGCCGT GCTCAGCTTC CTCTGCTGCG GGTGTCTCCG GCTGGGCATG	1040
CGAGGGCCCC GGGACTGCCT GGCCCGGGCC GTCGAGGCTC ACTCCGGAGC TTCCACCACC	1100
GACAGCTCTC TGAGGCCAAG GGACAGCTTT CGCGGCTCCC GCTCGCTCAG CTTTCGGATG	1160
CGGGAGCCCC TGTCCAGCAT CTCCAGCGTG CGGAGCATCT GAAGTTGCAG TCTTGCGTGT	1220
GGATGGTGCA ACCACCGGGT GCGTGCCAGG CAGGCCCTCC TGGGGTACAG GAAGCTGTGT	1280
GCACGCAACC TCGCCCTGTA TGGGGAGCAG GGAACGGGAC AGGCCCCCAT GGAATTGCCC	1340
GGTGGCCTCT CGGGGCTTCT GACGCCATAT GGAATTGCCC ATTGCCTATG GCTCACCTTG	1400
GACAAGGAGG CAACCACCCC ACCTCCCCGT AGGAGCAGAG AGCACCTTGG TGTGGGGGCG	1460
AGTGGGTTCC CCACAACCCC GCTTCTGTGT GATTCTGGGG AAGTCCCGGC CCCTCTCTGG	1520
GCCTCAGTAG GGCTCCCAGG CTGCAAGGGG TGGACTGTGG GATGCATGCC CTGGCAACAT	1680
TGAAGTTCGA TCATGGTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAA	1735

FIG.3B

SUBSTITUTE SHEET (RULE 26)

7/7

1 MNATGTPVAPESCQQLAAGGHSRLIVLHYNHSGRLAGRGGPEDGGLGALR 50
 |.:|.:|:.... :.. :. :|| |||..|:|. :.:|: :.
 1 MGPTSVPLVKAHRSSVSDYVNYDIIVRHNYTGKLNISADKEN.SIKLTS 49

 51 GLSVAASCLVVLENLLVLAAITSHMRSQRWVYYCLVNITMSDLLTGAAYL 100
 .: : :|:..|||:..| .| .: :| :|| :|:..|||..|..||
 50 VVFILICCFIILENIFVLLTIWTKKFKHRPMYYFIGNLALSDLLAGVAYT 99

 101 ANVLLSGARTFRLAPAQWFLRKGLLFTALAASTFSLLFATGLRFATMVRP 150
 ||:||||| |.:|. |||..| .| :|. ||. |||..| .| |.:|:|:
 100 ANLLLSGATTYKLTPAQWFLREGSMFVALSASFVSLLAIAIERYITMLKM 149

 151 VAESGATKTSRVYGFIGLCWLLAALLGMLPLLGNCLCAFDRCSSLLPLY 200
 ..|. .. |: :|: ||:.. :|| ||:..|||:|:..|:|:|:
 150 KLHNGS.NNFRLFLISACWVISLILGGLPIMGWNCISALSSCSTVLPLY 198

 201 SKRYILFCLVIFAGVLATIMGLYGAIIFRLVQASGQKAPRPAARRKARR.. 248
 |:||||| .:|. :| .|: ||. |:..|:..:.. :.. :..|:|
 199 HKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRLTFRKNISKASRSS 248

 249LLKTVLMILLAFLVCWGPLFGLLLADVFGSNLWAQEYLRGMDWILA 294
 |||||:..| .|:..||:||| ||| || |:..:.. :..| :.:|:
 249 ENVALLKTVIIVLSVFIACWAPLFILLLLDV.GCKVKTCDILFRAEYFLV 297

 295 LAVLNSAVNPPIYSFRSREVCRAVLSFLCCGCLRLGMRGPGDCLARAVEA 344
 |||||:..|||:.. :|: ||:..:..| .| :.: :|:|
 298 LAVLNSGTNPPIYTLTNKEMRRAFIRIMSCCKCPSG..DSAGKFKRPIIA 345

 345 ...HSGASTTDSSLRPRDSFRGSRSLSFMRREPLSSIS 379
 | ..:..|| ..:|. |... :. :.:| |
 346 GMEFSRSKSDNSSHPQKDE..GDNPETIMSSGNVNSSS 381

FIG.4



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C12Q 1/68, C07K 14/705, 16/28	A3	(11) International Publication Number: WO 98/50549 (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: PCT/US98/09048 (22) International Filing Date: 7 May 1998 (07.05.98) (30) Priority Data: 08/852,824 7 May 1997 (07.05.97) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). LI, Yi [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). (74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 6 April 2000 (06.04.00)
(54) Title: TWO HUMAN G-PROTEIN COUPLED RECEPTORS: EBV-INDUCED GPCR 2 (EBI-2) AND EDG-1-LIKE GPCR (57) Abstract <p>Two human G-protein coupled receptor polypeptides and DNA (RNA) encoding each of such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the nucleic acid sequence of each of the G-protein coupled receptors.</p> <pre> 1 MQAVDNLTSAP...GNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLA 46 : 3 IQMANNFTPPSATPQGNDCDLYAHHSTARIVMPLHYSLVFIIIGLVGNLLA 52 47 MRIFFOIRSKSN.FIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTF 95 : 53 LVVIVONRRKKINSTLYSTNLVSDILFTTALPTRIAYYAMGFWDWRIGDA 102 96 VQCVTSVIFYFTMYISISFLGLITIDRYQKTTTRPFKTSNPKNLLGAKILS 145 : 103 LCRITALVFYINTYAGVNFMTCLSIDRFIAVVHPLRYNKKRIEHAKGVC 152 146 VVIWAFMFLSLPNMI...LTNRQPRDKNVKCSFLKSEFGLVWHEIVNYI 193 : 153 IFVWILVFAQTLPLLINPMSKQEAERITCMEYPNFEETKSLPWILLGACF 202 194 CQVIFWINFLIVICYTLITKELYRSYVTRGVGK...VPRKKVNVKVFII 241 : 203 IGYVL...PLIILICYSOICCKLFRITAKQNPLTEKSGVNNKALNTIILII 250 242 IAVFFICFVPFHFAIPYLSQTR...DVFDCTAENTLFYVKESTLWLTS 289 : 251 V.VFVLCFTPYHVAIIQHMIKKLRFNFLECSQRHSFQISLHFTVCLMNF 299 290 NACLDPFIYFFLCKSFRNSLISMLKCPNSATLSQDNRRKKEQDGGDPNEE 339 : 300 NCCMDPFIYFFACKGYKRKVMRMLKRQVS.VSISAVKSAPEENSREMT 348 340 TPM 342 : : 349 TQM 351 </pre>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
/US 98/09048

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C12Q1/68 C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL - EMBEST8 Entry Hs162g01b, Acc.No. D81412, 7 February 1996 FUJIWARA T., ET AL.: "Human fetal brain cDNA 5'-end GEN-162G01." XP002076080 see the whole document ---	1,2,4-7, 11,12, 14-16
A	WO 94 12519 A (BRIGHAM & WOMENS HOSPITAL) 9 June 1994 see the whole document ---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

1 September 1998

Date of mailing of the international search report

26. 01. 99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

INTERNATIONAL SEARCH REPORT

International Application No

/US 98/09048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EMBL- EMBEST3 Entry Aa810452, Acc.No. g2875724, 16 February 1998 STRAUSBERG, R.: "ob94e01.s1 NCI CGAP GCB1 Homo sapiens cDNA clone IMAGE:1339032." XP002076081 see the whole document</p> <p style="text-align: center;">---</p>	<p>1,2,4-7, 11,12, 14-16</p>
P,X	<p>NELSON, P.S. ET AL.: "An expressed-sequence-tag database of the human prostate: sequence analysis of 1168 cDNA clones." GENOMICS, vol. 47, no. 1, 1 January 1998, pages 12-25, XP002076079 see the whole document -& DATABASE EMBL - EMBEST1 Entry AA447306, Acc.No. AA447306, 7 April 1998 NELSON, P.S. ET AL.: "BS.B12R PN001-Normal Human Prostate Homo sapiens cDNA clone BS.B12 5'." XP002076082 see the whole document</p> <p style="text-align: center;">-----</p>	<p>1,2,4-7, 11,12, 14-16</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/09048

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

2,9,12 and 1,4-8,11,14-19,21 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 2,9,12 and 1,4-8,11,14-19,21 partially

An isolated polypeptide comprising a sequence which is at least 95% homologous to seq. 2, a polynucleotide encoding it, a recombinant vector comprising the nucleic acid and method for making the vector, a recombinant host comprising said nucleic acid, a method of producing the encoded peptide using said host, an antibody against said peptide, an antagonist for said peptide, and a process for diagnosing a disease or susceptibility to a disease comprising determining the presence of a mutation in said nucleic acid.

2. Claims: 3,10,13 and 1,4-8,11,14-19,21 partially

An isolated polypeptide comprising a sequence which is at least 95% homologous to seq. 4, a polynucleotide encoding it, a recombinant vector comprising the nucleic acid and method for making the vector, a recombinant host comprising said nucleic acid, a method of producing the encoded peptide using said host, an antibody against said peptide, an antagonist for said peptide, and a process for diagnosing a disease or susceptibility to a disease comprising determining the presence of a mutation in said nucleic acid.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No.

T/US 98/09048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9412519 A	09-06-1994	AU 5325694 A US 5744301 A	22-06-1994 28-04-1998
